

CITATION REPORT

List of articles citing

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

DOI: 10.1182/blood.v72.2.567.567
Blood, 1988, 72, 567-572.

Source: <https://exaly.com/paper-pdf/20206597/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2048	The Role of RAR α and Its Fusion Partners in Acute Promyelocytic Leukemia. 325-378		
2047	Modulation of Growth and Differentiation by Retinoids and Cytokines. 1991 , 127-138		4
2046	Studies on the relationship between protein kinase C and differentiation of human promyelocytic leukemia cells induced by retinoic acid. 1989 , 13, 869-74		29
2045	Induction of differentiation in HL-60 cells by retinoic acid and lymphocyte-derived differentiation-inducing factor but not by recombinant G-CSF and GM-CSF. 1989 , 13, 1091-7		11
2044	Triple combination of retinoic acid + low concentration of cytosine arabinoside + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. 1989 , 7, 429-40		12
2043	Retinoic acid therapy for promyelocytic leukaemia. 1989 , 2, 746-7		103
2042	Triple combination of retinoic acid, low concentration of cytarabine and dimethylformamide induces differentiation of human acute myeloid leukaemic blasts. 1990 , 36, 51-7		4
2041	Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR- α). 1990 , 10, 2154-63		290
2040	Retinoic acid acylation: retinoylation. 1990 , 189, 233-8		22
2039	The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. 1990 , 347, 558-61		1134
2038	Uptake of chylomicron remnant retinyl ester via the low density lipoprotein receptor: implications for the role of vitamin A as a possible preventive for some forms of cancer. 1990 , 228, 207-10		18
2037	Reduction of leukemia cell growth in a patient with acute promyelocytic leukemia treated by retinol palmitate. 1990 , 14, 595-600		17
2036	Triple combination of retinoic acid + 6-thioguanine + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. 1990 , 14, 109-17		17
2035	Difference in effects of interferon-alpha and interferon-gamma on the induction of differentiation of retinoic acid-treated acute myeloid leukemia cells in primary culture. 1990 , 14, 785-94		8
2034	Differentiating agents in the treatment of leukemia. 1990 , 14, 717-9		30
2033	Differentiating agents in the treatment of leukemia and myelodysplastic syndromes. 1990 , 14, 731-3		6
2032	Triple combination of retinoic acid plus actinomycin D plus dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture. 1990 , 26, 26-30		13

2031	The unique aspects of acute promyelocytic leukemia. 1990 , 8, 1913-21	135
2030	Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases. 1990 , 2, 399-405	2
2029	Growth and differentiation of human myeloid leukemia cell line HL60. 1990 , 190, 118-30	32
2028	Effect of 5-aza-2'-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. 1990 , 54, 21-8	29
2027	Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. 1990 , 336, 1440-1	116
2026	Pathobiology of myelodysplastic syndromes. 1990 , 44, 69-83	4
2025	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. 1991 , 66, 663-74	1204
2024	Potential of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. 1991 , 27, 53-7	50
2023	Application thérapeutique de l'acide rétinique dans la leucémie aiguë promyélocytaire. 1991 , 6, 17-21	
2022	Management of patients with myelodysplastic syndromes. 1991 , 66, 485-97	12
2021	Inherited bleeding disorders. 1991 , 1, 192-197	
2020	Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells. 1991 , 45, 145-56	51
2019	Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia. 1991 , 45, 169-77	8
2018	A biological hypothesis for the FAB classification of acute myeloid leukaemias. 1991 , 35, 73-6	
2017	Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). 1991 , 324, 1385-93	1073
2016	Retinoylation of proteins in leukemia, embryonal carcinoma, and normal kidney cell lines: differences associated with differential responses to retinoic acid. 1991 , 285, 105-10	38
2015	Retinoylation of the cAMP-binding regulatory subunits of type I and type II cAMP-dependent protein kinases in HL60 cells. 1991 , 290, 293-302	48
2014	Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. 1991 , 178, 686-93	59

2013	Gs alpha availability to cholera toxin-catalysed ADP-ribosylation is decreased in membranes of retinoic acid-treated leukemic cell lines HL-60 and THP-1. A posttranslational effect. 1991 , 42, 2141-6	10
2012	Oncogenic conversion of transcription factors by chromosomal translocations. 1991 , 66, 619-22	180
2011	The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. 1991 , 66, 675-84	1200
2010	Leukemia and the disruption of normal hematopoiesis. 1991 , 64, 337-50	302
2009	Induction of differentiation of human myeloid leukemia HL-60 cells by novel pyrimidine nucleoside analogs. 1991 , 1094, 1-7	15
2008	Regulation of gene expression by retinoic acid receptors. 1991 , 10, 623-38	95
2007	All-Trans-Retinoic Acid Treatment for Patients with Acute Promyelocytic Leukemia. 1991 , 121-126	
2006	Acute promyelocytic leukemia: an update. 1991 , 2, 392-3	1
2005	Epidemiology of acute promyelocytic leukemia in Italy. APL Collaborating Group. 1991 , 2, 405-8	14
2004	Autologous bone marrow transplantation. 1991 , 15, 5-57	5
2003	A road less travelled: Normal phase microbore liquid chromatography-mass spectrometry using direct liquid introduction. 1991 , 10, 177-184	8
2002	Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays. 1991 , 117, 227-31	14
2001	The scientific bases of cancer management: at the interface between fundamental research and clinical practice. 1991 , 117, 275-89	3
2000	Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH) ₂ vitamin D ₃ . 1991 , 15, 409-18	35
1999	Pharmacological studies of retinol palmitate and its clinical effect in patients with acute non-lymphocytic leukemia. 1991 , 15, 463-71	15
1998	Treatment of acute promyelocytic leukemia with all-trans retinoic acid. 1991 , 15, 655-7	20
1997	Response to trans-retinoic acid in an AMLM3 patient resistant to cis-retinoic acid. 1991 , 15, 765	2
1996	Relationship between clonality and transformation in acute leukemia. 1991 , 15, 1-7	9

1995	Synergistic effect of retinoic acid and 1,25-dihydroxyvitamin D3 on the differentiation of the human monocytic cell line U937. 1991 , 15, 1145-52	61
1994	Recombinant human interleukin-6 enhances the antiproliferation and differentiation inducing effects of retinoic acid in HL-60 human myeloid leukaemic cells. 1991 , 18, 847-51	6
1993	Low-dose chemotherapy and differentiating agents. 1991 , 4, 47-68	7
1992	Chemotherapy of acute myelogenous leukaemia. 1991 , 4, 97-113	6
1991	Practical aspects and diagnostic significance of in vitro manipulation of progenitors in human acute myeloid and lymphoid leukaemia. 1991 , 4, 637-53	6
1990	Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype. 1991 , 78, 494-9	39
1989	Restitution of normal marrow morphology and karyotype in acute refractory acute promyelocytic leukaemia with all-trans retinoic acid. 1991 , 78, 572	3
1988	Treatment of acute promyelocytic leukaemia relapsing after allogeneic bone marrow transplantation with all-trans-retinoic acid: suppression of the leukaemic clone. 1991 , 79, 331-4	6
1987	Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. 1991 , 79, 382-9	16
1986	Retinyl esters in chylomicron remnants inhibit growth of myeloid and lymphoid leukaemic cells. 1991 , 21, 574-9	9
1985	Molecular assignment of a translocation breakpoint in acute myeloid leukemia with t(8;21). 1991 , 3, 163-7	18
1984	Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. 1991 , 3, 332-7	75
1983	13-cis-retinoic acid in the treatment of elderly patients with acute myeloid leukemia. A phase II pilot study of the Eastern Cooperative Oncology Group. 1991 , 67, 1484-6	11
1982	13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma. 1991 , 67, 2490-4	19
1981	Biology of pediatric peripheral neuroectodermal tumors. 1991 , 10, 311-9	50
1980	Dietary retinol: prevention or promotion of carcinogenesis in humans?. 1991 , 2, 443-50	47
1979	Localization of the cellular retinoic acid binding protein (CRABP) gene relative to the acute promyelocytic leukemia-associated breakpoint on human chromosome 15. 1991 , 87, 201-4	14
1978	New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia. 1991 , 41, 531-6	7

1977	Prognostic Factors in Acute Promyelocytic Leukemia: A Retrospective Study of 67 Cases. 1991 , 4, 249-56	36
1976	Toxicity and antitumor activity of liposome-entrapped retinoid Ro13-7410. 1991 , 7, 151-7	3
1975	Treatment of Acute Promyelocytic Leukemia: A Report of 70 Cases. 1991 , 4, 239-48	56
1974	The clinical significance of biological characteristics of the cells in acute myeloid leukemia. 1991 , 42, 381-9	5
1973	Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. 1991 , 254, 1371-4	419
1972	The maturation of differentiation therapy. 1992 , 327, 422-4	9
1971	RARA and PML genes in acute promyelocytic leukemia. 1992 , 8, 253-60	22
1970	Brief report: severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). 1992 , 327, 385-7	42
1969	Retinoids selective for retinoid X receptor response pathways. 1992 , 258, 1944-6	310
1968	The present status in all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia patients: further understanding and comprehensive strategy are required in the future. 1992 , 8, 247-52	3
1967	The expression and possible roles of protein kinase C in haematopoietic cells. 1992 , 8, 201-11	21
1966	Regulation of gap junctional communication in Syrian hamster embryo cells by retinoic acid and 12-O-tetradecanoylphorbol-13-acetate. 1992 , 13, 199-203	11
1965	A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. 1992 , 6, 2258-69	121
1964	Retinoids and cancer therapy. 1992 , 84, 1306-7	4
1963	Abstracts. 1992 , 10, 1-41	30
1962	Physiological and clinical aspects of vitamin A and its metabolites. 1992 , 29, 185-215	31
1961	The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers. 1992 , 10, 417-29	7
1960	Retinoids in cancer prevention and therapy. 1992 , 3, 513-26	158

1959	Retinoids--"differentiation agents" for cancer treatment and prevention. 1992 , 304, 202-13	20
1958	Treatment of Acute Promyelocytic Leukemia. 1992 , 15, 356-363	4
1957	Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. 1992 , 89, 2694-8	193
1956	Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. 1992 , 12, 3743-9	84
1955	Prolonged Complete Remission of Relapsing Acute Promyelocytic Leukemia Induced by 13-cis-retinoic Acid. 1992 , 6, 427-430	
1954	New drugs in acute myelogenous leukemia: a review. 1992 , 32, 296-309	7
1953	Retinoids in cancer treatment. 1992 , 32, 868-88	55
1952	Covalent modification of proteins by ligands of steroid hormone receptors. 1992 , 89, 10807-11	19
1951	Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. 1992 , 12, 800-10	76
1950	The "retinoic acid syndrome" in acute promyelocytic leukemia. 1992 , 117, 292-6	485
1949	Retinoic acid receptors: transcription factors modulating gene regulation, development, and differentiation. 1992 , 27, 309-50	88
1948	Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid. 1992 , 99, 1463-7	23
1947	All-trans retinoic acid (ATRA) therapeutical effect in acute promyelocytic leukemia. 1992 , 46, 201-9	14
1946	Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo. 1992 , 22, 229-34	19
1945	Protein kinase C activity during sphinganine potentiation of retinoic acid-induced differentiation in a human leukemia cell line (HL-60). 1992 , 51, 415-22	6
1944	All-trans retinoic acid and side-effects. 1992 , 339, 1239-40	14
1943	Hypercalcaemia due to all-trans retinoic acid. 1992 , 339, 308-9	44
1942	Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. 1992 , 340, 1437-8	181

1941	Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers: development of DNA double-strand breaks. 1992 , 46, 183-92	16
1940	Retinoids for the future: oncology. 1992 , 27, S34-7	14
1939	The next generation: new chemotherapy agents for the 1990s. 1992 , 8, 83-94	2
1938	Acute myelogenous leukemia: current treatment and future directions. 1992 , 92, 286-95	28
1937	Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia.. 1992 , 11, 1397-1407	197
1936	Retinoid therapy for acute promyelocytic leukemia: a coming of age for the differentiation therapy of malignancy. 1992 , 117, 338-40	5
1935	All-trans-retinoic acid: what is it good for?. 1992 , 10, 1659-61	8
1934	Retinoids in cancer therapy. 1992 , 10, 839-64	433
1933	Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. 1992 , 10, 1666-73	118
1932	The Biological Therapy of Cancer. 1992 , 3, 26-33	1
1931	Bleeding Problems in the Cancer Patient. 1992 , 6, 1315-1328	26
1930	Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. 1992 , 12, 193-215	32
1929	Action of exogenous differentiating agents on gene expression in cancer cells. 1992 , 13, 189-214	6
1928	Transcriptional regulation by the nuclear receptor superfamily. 1992 , 3, 597-602	40
1927	Therapy of acute myelogenous leukemia. 1992 , 6, 15-25	16
1926	Transcription factors, translocations and haematological malignancies. 1992 , 6, 118-24	11
1925	All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy. 1992 , 10, 63-9	22
1924	Retinyl acetate and all-trans-retinoic acid enhance erythroid colony formation in vitro by circulating human progenitors in an improved serum-free medium. 1992 , 10, 286-91	13

1923	Synergistic induction of the differentiation of WEHI-3B D+ myelomonocytic leukemia cells by retinoic acid and granulocyte colony-stimulating factor. 1992 , 16, 571-6	27
1922	The effects of microtubule disrupting drugs on the differentiation of HL-60 leukemia cells. 1992 , 16, 929-35	14
1921	Strategies in the treatment of acute myelogenous leukemia. 1992 , 16, 1143-53	17
1920	Higher cure rates in acute leukemia: now more probable with increasingly effective induction therapy. 1992 , 21, 273-7	1
1919	Hematopoietic transcription regulators and the origins of leukemia. 1992 , 12, 167-90	11
1918	Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events. 1992 , 64, 270-2	30
1917	All-trans retinoic acid in acute promyelocytic leukemia: preliminary results in Cuba. 1992 , 65, 121-3	7
1916	Acute promyelocytic leukaemia. 1992 , 81, 315-20	38
1915	Haemopoietic growth factors in acute myeloblastic and lymphoblastic leukaemia. 1992 , 5, 599-618	4
1914	Transforming growth factor beta and interleukin-1: a paradigm for opposing regulation of haemopoiesis. 1992 , 5, 703-21	20
1913	Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia. 1992 , 5, 833-56	11
1912	Association of thyroid disease with acute leukemia. 1992 , 39, 102-7	24
1911	Frequent rearrangements of retinoic acid receptor alpha gene and myl gene, and rare mutations of RAS and FMS genes in acute promyelocytic leukemia. 1992 , 40, 252-8	8
1910	Case report: all-trans retinoic acid, hyperleukocytosis, and marrow infarction. 1992 , 41, 305-6	6
1909	The role of emerging technologies in the diagnosis and staging of neoplastic diseases. 1992 , 69, 1520-6	5
1908	Four years' experience with the treatment of all-trans retinoic acid in acute promyelocytic leukemia. 1993 , 43, 183-9	14
1907	Treatment of acute promyelocytic leukemia with all-trans retinoic acid: successful control of hyperleukocytosis and leukostasis syndrome with leukaphereses and hydroxyurea. 1993 , 43, 323-4	4
1906	Genetic damage and escape from proliferation control. 1993 , 53, 161-177	

1905	Chromosomal biomarkers in the clonal evolution of head and neck squamous neoplasia. 1993 , 17F, 213-22	26
1904	Tretinoin: A review of in vivo pharmacological studies. 1993 , 30, 238-243	2
1903	Tretinoin: A review of preclinical toxicological studies. 1993 , 30, 244-251	6
1902	The past, the present, the future. 1993 , 71, 1396-9	2
1901	Rearrangements of the RARA and PML genes in a cytogenetic variant of acute promyelocytic leukemia. 1993 , 6, 118-20	11
1900	Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse. 1993 , 71, 774-9	3
1899	Terson's syndrome in a patient with acute promyelocytic leukemia on all-trans retinoic acid treatment. 1993 , 84, 373-8	9
1898	The molecular genetics of acute promyelocytic leukemia. 1993 , 7, 87-93	31
1897	Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. 1993 , 68, 530-6	20
1896	Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. 1993 , 54, 115-22	11
1895	9-cis and all-trans retinoic acid induce a similar phenotype in human teratocarcinoma cells. 1993 , 54, 123-9	14
1894	Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. 1993 , 54, 115-122	15
1893	9-cis and all-trans retinoic acid induce a similar phenotype in human teratocarcinoma cells. 1993 , 54, 123-129	17
1892	Management of myelodysplastic syndromes. 1993 , 84, 191-6	15
1891	Stem cell renewal and determination during clonal expansion in normal and leukaemic haemopoiesis. 1993 , 26, 399-425	26
1890	Differentiation therapy: retinoic acid-induced remission. 1993 , 3, 185-7	3
1889	Delineation of translocation t(15; 17) in acute promyelocytic leukemia by chromosomal in situ suppression hybridization. 1993 , 17, 359-64	5
1888	Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines. 1993 , 17, 949-57	8

1887	Thermal stress as an inducer of differentiation of U937 cells. 1993 , 17, 649-56	17
1886	Induction of the differentiation of HL-60 and WEHI-3B D+ leukemia cells by lithium chloride. 1993 , 17, 403-10	17
1885	Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. 1993 , 17, 441-3	24
1884	Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. 1993 , 17, 749-57	29
1883	Inhibition of granulocytic differentiation of acute promyelocytic leukemia cells in primary culture by transforming growth factor-beta. 1993 , 17, 1051-6	
1882	Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study on BM mononuclear cells and on isolated CD34+ BM cells. 1993 , 66, 61-6	34
1881	Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. 1993 , 66, 165-70	28
1880	The retinoic acid analog CBS-211A potentiates the 1 alpha,25-dihydroxyvitamin D3-induced differentiation of U937 cells. 1993 , 38, 91-9	4
1879	New targets for cancer therapy. 1993 , 14, 373-449	8
1878	Enhancement by retinoid of hemin-induced differentiation of human leukemia K562 cell line. 1993 , 330, 81-4	10
1877	Nuclear receptor/AP-1 interaction. 1993 , 14, 651-8	309
1876	Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. 1993 , 11, 321-31	288
1875	Acute promyelocytic leukemia. 1993 , 329, 177-89	787
1874	Détection par HPLC des isomères de l'acide réinoïque dans le milieu biologique des cellules leucémiques myélodées humaines. 1993 , 8, 161-167	
1873	Retinoid receptors and acute promyelocytic leukaemia. 1993 , 29A, 2046-54	3
1872	Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase. 1993 , 48, 323-6	19
1871	Chapter 5 Biochemical ageing in the retina and RPE. 1993 , 12, 101-131	6
1870	Dietary modulation of the symptoms of cadmium toxicity in rats: Effects of vitamins A, C, D, D hormone, and fluoride. 1993 , 13, 839-850	6

1869	The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. 1993 , 74, 423-31	518
1868	Retinoic acid syndrome. 1993 , 341, 1289-90	11
1867	Multiple thrombosis in acute promyelocytic leukaemia after tretinoin. 1993 , 342, 114-5	35
1866	Tretinoin toxicity in children with acute promyelocytic leukaemia. 1993 , 342, 1394-5	80
1865	Retinoic acid receptor alpha in acute promyelocytic leukemia. 1993 , 684, 149-56	1
1864	Retinoids and cancer: a basis for differentiation therapy. 1993 , 11, 590-8	31
1863	Recent advances in the chemistry and biology of retinoids. 1993 , 30, 1-55	3
1862	Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1. 1993 , 9, 141-8	20
1861	Selfish cells in altruistic cell society - a theoretical oncology. 1993 , 3, 441-55	1
1860	Retinol and retinyl esters in rabbit bone marrow and blood leukocytes. 1993 , 53, 515-9	4
1859	Induction of interleukin-8 expression in neuroblastoma cells by retinoic acid: implication of leukocyte chemotaxis and activation. 1993 , 34, 720-4	14
1858	Use of X-linked clonal analysis in acute promyelocytic leukemia. 1993 , 11, 339-43	
1857	What is the best treatment for acute promyelocytic leukemia?. 1993 , 11 Suppl 2, 29-35	10
1856	Effects of Spinach Extract on the Differentiation of the Human Promyelocytic Cell Line, HL-60. 1993 , 57, 1951-1952	7
1855	New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. 1993 , 11, 27-36	51
1854	Biological Effect of 9-cis-Retinoic Acid and 9,13-di-cis-Retinoic Acid on Human Acute Promyelocytic Leukemia Cell Line HL-60.. 1993 , 69, 185-190	1
1853	Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. 1993 , 67, 1293-8	23
1852	Formation of retinoid X receptor homodimers leads to repression of T3 response: hormonal cross talk by ligand-induced squelching. 1993 , 13, 7698-707	100

1851	All-trans retinoic acid as an alternative to chemotherapy in the treatment of acute promyelocytic leukemia. 1993 , 10, 363-7	1
1850	Use of trans-retinoic acid in the treatment of acute promyelocytic leukemia. 1993 , 27, 211-4	7
1849	Current Progress in the Treatment of Adult Acute Leukemia in Japan. 1993 ,	
1848	The role of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. 1993 , 89 Suppl 1, 22-7	16
1847	Chimeric retinoic acid/thyroid hormone receptors implicate RAR-alpha 1 as mediating growth inhibition by retinoic acid.. 1993 , 12, 3459-3466	36
1846	The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. 1993 , 90, 9345-9	61
1845	PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR.. 1993 , 12, 3171-3182	237
1844	All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. 1993 , 11, 1489-95	47
1843	Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. 1993 , 11, 959-66	71
1842	The Discovery and Development of New Antileukemic Drugs. 1993 , 7, 233-254	
1841	Advances in the Diagnosis of Acute Leukemia. 1993 , 7, 1-46	11
1840	All-trans-Retinoic Acid as a Frontline Therapy for Acute Promyelocytic Leukemia. 1994 , 4, 237-242	
1839	Retinoic acid receptors. 1994 , 28-58	1
1838	Molecular Pathogenesis of Acute Promyelocytic Leukemia1. 1994 , 148-159	
1837	All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. 1994 , 120, 278-86	199
1836	ALL-Trans Retinoic Acid (ATRA) in the Treatment of Myelodysplastic Syndromes: Results in 5 Cases. 1994 , 17, 515-520	2
1835	Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene.. 1994 , 13, 5570-5580	39
1834	Prophylaxis of symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with all-trans retinoic acid. 1994 , 92, 109-12	3

1833	Cytogenetic and molecular analysis of pediatric neoplasms: diagnostic and clinical implications. 1994 , 14, 167-76	8
1832	Butyrate-induced differentiation in leukemic myeloid cells - in-vitro and in-vivo studies. 1994 , 4, 1387-91	4
1831	Modulation of lipopolysaccharide-mediated cytokine secretions by retinoic Acid. 1994 , 4, 815-20	
1830	Application of chemical immunomodulators to the treatment of cancer and AIDS. 1994 , 12, 620-43	9
1829	The role of oncogenes in hematologic malignancies. 1994 , 45, 1-11	3
1828	PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. 1994 , 91, 1178-82	162
1827	Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. 1994 , 8, 2831-41	226
1826	Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia. 1994 , 15, 143-7	7
1825	Expression of the annexin VIII gene in acute promyelocytic leukemia. 1994 , 13, 381-6	14
1824	Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia. 1994 , 13, 353-6	13
1823	A perspective on benzene leukemogenesis. 1994 , 24, 177-209	100
1822	Differentiation therapy of myelodysplastic syndromes with retinoic acid. 1994 , 14, 401-9	16
1821	Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. 1994 , 14, 453-6	32
1820	Molecular mechanisms of dominant negative activity by nuclear hormone receptors. 1994 , 8, 1450-4	71
1819	All-trans retinoic acid and induction of apoptosis in acute promyelocytic leukemia cells. 1994 , 14, 503-7	20
1818	Clinical relevance of the PML/RAR-a gene rearrangement in acute promyelocytic leukaemia. 1994 , 12, 327-32	8
1817	A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. 1994 , 331, 1680-4	86
1816	The identification of glioblastoma-associated, fucose-containing glycoproteins induced by retinoic acid. 1994 , 21, 311-27	6

1815	Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid. 1994 , 8, 70-8	7
1814	Functional characteristics of in vivo induced neutrophils after differentiation therapy of acute promyelocytic leukemia with all-trans-retinoic acid. 1994 , 73, 1206-12	13
1813	All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. 1994 , 73, 2946-52	40
1812	New chemotherapeutic agents for breast cancer. 1994 , 74, 1164-76	17
1811	Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans' cell histiocytosis. 1994 , 74, 1650-2	2
1810	Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. 1994 , 74, 1882-6	69
1809	Myelodysplastic syndrome transforming to acute promyelocytic-like leukemia with trisomy and rearrangement of chromosome 11. 1994 , 10, 15-25	12
1808	Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogs. 1994 , 56, 427-35	29
1807	Treatment of refractory undifferentiated acute myelogenous leukemia with all-trans-retinoic acid. 1994 , 45, 177-80	12
1806	Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. 1994 , 46, 184-8	33
1805	Bone marrow necrosis in two patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid. 1994 , 47, 50-5	18
1804	Synthesis of some retinoids bearing different heterocyclic rings with anticancer activity. 1994 , 29, 773-780	9
1803	Determination of orally administered all-trans-retinoic acid in human plasma by high-performance liquid chromatography. 1994 , 656, 239-44	13
1802	Simultaneous determination of 13-cis- and all-trans-retinoic acids and retinol in human serum by high-performance liquid chromatography. 1994 , 657, 53-59	17
1801	Sphinganine potentiation of cellular differentiation induced by various anti-leukemia drugs in human leukemia cell line HL-60. 1994 , 350, 575-81	
1800	Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. 1994 , 18, 587-96	60
1799	Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: increased inhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease. 1994 , 18, 741-8	11
1798	1,25(OH) ₂ -16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. 1994 , 18, 453-63	44

1797	A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. 1994 , 372, 107-11	300
1796	Modulation of growth factor receptors on acute myeloblastic leukemia cells by retinoic acid. 1994 , 85, 378-83	10
1795	Translocation of the RAR alpha locus to the PML or PLZF gene in acute promyelocytic leukaemia. 1994 , 86, 451-60	31
1794	Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy. 1994 , 86, 681-2	49
1793	Marked basophilia in acute promyelocytic leukaemia treated with all-trans retinoic acid: molecular analysis of the cell origin of the basophils. 1994 , 86, 870-2	12
1792	A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. 1994 , 76, 333-43	719
1791	Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. 1994 , 76, 345-56	606
1790	Haemorrhagic gastritis in two patients treated with all-trans-retinoic acid in acute promyelocytic leukaemia. 1994 , 24, 314-5	2
1789	Interaction of liposome-associated all-trans-retinoic acid with squamous carcinoma cells. 1994 , 34, 527-34	34
1788	Modulation of all-trans retinoic acid pharmacokinetics by liarozole. 1994 , 34, 522-6	51
1787	Regulation of the 28 kDa heat shock protein by retinoic acid during differentiation of human leukemic HL-60 cells. 1994 , 337, 184-8	40
1786	Acute promyelocytic leukaemia, tretinoin, and granulocyte colony-stimulating factor. 1994 , 343, 173-4	12
1785	Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. 1994 , 15, 61-79	343
1784	Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy. 1994 , 30, 293-7	66
1783	Stability Indicating HPLC Assay for Retinoic Acid in Hard Gelatine Capsules Containing Lactose and as Bulk Drug Substance. 1994 , 20, 2395-2408	8
1782	Pharmacokinetics, Tissue Distribution, and Toxicology of Tretinoin Incorporated in Liposomes. 1994 , 4, 689-700	13
1781	3,5,3'-Triiodothyronine stimulates retinoic acid-induced differentiation in HL-60 cells. 1994 , 103, 119-23	4
1780	CANCER CHEMOPREVENTION BY NATURAL-PRODUCTS (REVIEW). 1994 , 1, 1139	7

1779	Biological Effect of Geometrical Isomers of Retinoic Acid on Human Promyelocytic Leukemia (HL-60) Cells.. 1994 , 70, 81-86	2
1778	Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. 1994 , 12, 1185-92	41
1777	Hemopoietic regulators and leukemia development: a personal retrospective. 1994 , 63, 41-91	6
1776	Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. 1994 , 91, 8428-32	109
1775	Retinoids in oncology: Experimental and clinical aspects. 1994 , 66, 995-1002	7
1774	PML, a growth suppressor disrupted in acute promyelocytic leukemia. 1994 , 14, 6858-67	266
1773	4-oxo retinoic acid for refractory acute promyelocytic leukemia in children with all-trans retinoic acid therapy. 1995 , 41, 493-8	5
1772	Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. 1995 , 67, 25-57	23
1771	All-trans retinoic acid shows multiple effects on the survival, proliferation and differentiation of human fetal CD34+ haemopoietic progenitor cells. 1995 , 90, 274-82	26
1770	Low incidence of MDR1 expression in acute promyelocytic leukaemia. 1995 , 90, 369-74	24
1769	Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. 1995 , 91, 878-84	35
1768	Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells. 1995 , 59, 61-9	35
1767	Successful management of an octogenarian with acute promyelocytic leukemia using all-trans retinoic acid. 1995 , 49, 263-5	1
1766	Itraconazole and retinoid resistance. 1995 , 50, 319-20	2
1765	Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. 1995 , 76, 602-8	16
1764	Retinoic acid and the differentiation of lymphohaemopoietic stem cells. 1995 , 17, 187-9	6
1763	A formal description of cell lineage and a hypothesis: all cell lineages are fixed. 1995 , 174, 237-260	1
1762	Influence of heredity on human sensitivity to environmental chemicals. 1995 , 25 Suppl 26, 102-14	25

1761	Direct evidence of altered bone metabolism caused by all-trans retinoic acid. 1995 , 13, 98-100	
1760	Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. 1995 , 70, 75-8	11
1759	Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. 1995 , 86, 400-5	29
1758	Simultaneous determination of all-trans and 13-cis retinoic acids and their 4-oxo metabolites by adsorption liquid chromatography after solid-phase extraction. 1995 , 666, 55-61	15
1757	Chemoenzymatic synthesis of enantiomers of a new retinoid to investigate the role of chirality in the biological response. 1995 , 5, 2801-2804	0
1756	Retinoic acid and retinoic acid receptors in development. 1995 , 10, 169-84	125
1755	Expression of cell surface antigens during the differentiation of HL-60 cells induced by 1,25-dihydroxyvitamin D3, retinoic acid and DMSO. 1995 , 19, 57-64	54
1754	Functional properties of HL60 cells matured with all-trans-retinoic acid and DMSO: differences in response to interleukin-8 and fMLP. 1995 , 19, 1-6	23
1753	Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. 1995 , 19, 65-72	64
1752	Functional characteristics of mature granulocytes in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. 1995 , 19, 505-11	4
1751	Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. 1995 , 19, 605-12	22
1750	Reverse transcription polymerase chain reaction for the diagnosis and molecular monitoring of the PML/RAR alpha fusion gene in acute promyelocytic leukemia. 1995 , 84, 91-4	4
1749	Effect of retinoic acid on the structure of N-glycans on the surface of human hepatocarcinoma cells and its enzymatic mechanism. 1995 , 121, 397-401	19
1748	Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. 1995 , 121, 696-8	38
1747	Acute promyelocytic leukemia: from clinic to molecular biology. 1995 , 13, 22-31	38
1746	RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.. 1995 , 14, 1187-1197	184
1745	Shifting the cancer paradigm: must we kill to cure?. 1995 , 13, 801-7	63
1744	Clinical Applications of All-Trans-Retinoic Acid in Hematologic Malignancies. 1995 , 2, 529-535	

1743	Retinoic acid inhibition of ex vivo human immunodeficiency virus-associated apoptosis of peripheral blood cells. 1995 , 92, 3051-5	46
1742	28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells. 1995 , 270, 1003-6	38
1741	The Genetics of Cancer. 1995 ,	2
1740	Treatment of acute promyelocytic leukemia in patients presenting at Vancouver General Hospital from 1983 to 1992. 1995 , 16, 439-44	1
1739	Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. 1995 , 16, 431-7	23
1738	Perspectives on genetics in china. 1995 , 29, 1-18	4
1737	Retinoic Acid potently stimulates the production of granulocyte-colony-stimulating factor in the human monocytic thp-1 cell-line. 1995 , 7, 45-50	
1736	Cancer cytogenetics and molecular-genetics - clinical implications (review). 1995 , 7, 1241-51	
1735	All-trans retinoic acid in the treatment of myelodysplastic syndromes. 1995 , 19, 277-80	21
1734	Low-dose cytosine arabinoside in patients with acute myeloid leukemia not eligible for standard chemotherapy. 1995 , 18, 465-9	5
1733	Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission. 1995 , 18, 249-57	19
1732	Retinoids in the treatment of acute promyelocytic leukemia. Review of the literature. 1995 , 207, 43-7	5
1731	Differentiation of extramedullary acute promyelocytic leukemia by all-trans-retinoic acid. 1995 , 18, 189-93	16
1730	Inhibition of oral carcinogenesis by the arotinoid mofarotene (Ro 40-8757) in male F344 rats. 1995 , 16, 1903-7	11
1729	Molecular sleuthing: tracking ovarian cancer progression. 1995 , 87, 1099-101	8
1728	Which progenitor is the target cell in the development of acute promyelocytic leukemia?. 1995 , 17, 251-4	2
1727	PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. 1995 , 181, 1965-73	84
1726	Biological activity and enzymatic hydrolysis of retinoates in vitro. 1995 , 3, 71-76	1

1725	Retinoids in oncology. 1995 , 31A, 834-5	2
1724	The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism. 1995 , 26, 327-33	11
1723	Retinoic acid enhances plasminogen activation on the cell surface. 1995 , 80, 47-56	6
1722	Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. 1995 , 50, 923-8	66
1721	Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. 1995 , 50, 897-923	34
1720	Can we prevent azole resistance in fungi?. 1995 , 346, 454-5	42
1719	Adult leukaemia in 1995: new directions. 1995 , 346, 455-6	1
1718	Successful treatment of retinoic acid syndrome with high-dose dexamethasone pulse therapy in a child with acute promyelocytic leukemia treated with ATRA. 1995 , 37, 384-7	3
1717	Differentiation induction of human leukemia cells (HL60) by a combination of 1,25-dihydroxyvitamin D3 and retinoic acid (all trans or 9-cis). 1995 , 53, 431-41	23
1716	Identification of a retinoic acid receptor alpha subtype specific agonist. 1996 , 39, 3035-8	51
1715	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. 1996 , 39, 2659-63	26
1714	Pathogenesis and management of acute promyelocytic leukemia. 1996 , 47, 555-65	51
1713	Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. 1996 , 100, 181-9	9
1712	Apoptosis induced by retinoic acid in Hep 3B cells in vitro. 1996 , 107, 149-59	34
1711	Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. 1996 , 52, 659-67	90
1710	The effect of dexamethasone on functional properties of HL60 cells during all-trans retinoic acid induced differentiation. Are there implications for the retinoic acid syndrome?. 1996 , 22, 139-49	7
1709	Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. 1996 , 429, 59-68	22
1708	The war on cancer. 1996 , 347, 1377-81	505

1707	Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia. 1996 , 27, 134-7	8
1706	Hematopoietic growth factors in leukemia. 1996 , 192, 734-42	4
1705	Retinoid actions and implications for prevention and therapy of oral cancer. 1996 , 25, 69-73	12
1704	Acquired Resistance to All-Trans Retinoic Acid Therapy in Acute Promyelocytic Leukemia. 1996 , 19, 10-13	
1703	Transgenic expression of PML/RARalpha impairs myelopoiesis. 1996 , 93, 7900-4	98
1702	Section Review: Oncologic, Endocrine & Metabolic: New advances in the treatment of acute promyelocytic leukaemia. 1996 , 5, 695-717	
1701	Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. 1996 , 93, 3624-9	157
1700	A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARalpha fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias.. 1996 , 15, 2707-2716	44
1699	The receptor-DNA complex determines the retinoid response: a mechanism for the diversification of the ligand signal. 1996 , 16, 4137-46	46
1698	Good things come in small packages. 1996 , 14, 182-3	
1697	Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features. 1996 , 14, 142-50	11
1696	Differentiation induction therapy with all-trans retinoic acid (ATRA) in a patient with secondary 11q23 leukemia. 1996 , 18, 405-8	2
1695	Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. 1996 , 124, 893-6	39
1694	Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents. 1996 , 74, 546-54	25
1693	Intensified Induction and Post-Remission Therapy for Acute Myeloid Leukaemia. 1996 , 1, 91-102	2
1692	Severe hepatobiliary complication in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. 1996 , 35, 499-501	4
1691	All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia. 1996 , 20, 243-8	11
1690	All-trans and 9-cis retinoic acid enhance 1,25-dihydroxyvitamin D3-induced monocytic differentiation of U937 cells. 1996 , 20, 665-76	40

1689	Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. 1996 , 20, 761-9	18
1688	Gliadin nanoparticles for the controlled release of all-trans-retinoic acid. 1996 , 131, 191-200	156
1687	Retinoid receptors in human lung cancer and breast cancer. 1996 , 350, 267-77	53
1686	Acute promyelocytic leukaemia in the all trans retinoic acid era. 1996 , 13, 233-40	2
1685	The efficacy of 9-cis retinoic acid in experimental models of cancer. 1996 , 38, 85-96	54
1684	Therapy of childhood acute myelogenous leukemias. 1996 , 73, 11-24	22
1683	Differentiation effect of acyclic retinoid on acute promyelocytic leukemia cells. 1996 , 73, 219-24	
1682	Translocation t(15;17) in acute myelogenous leukemia with atypical megakaryoblastic features: diagnostic, clinical, and therapeutic implications. 1996 , 92, 50-3	5
1681	Molecular and cytogenetic abnormalities in acute myeloid leukaemia and myelodysplastic syndromes. 1996 , 9, 1-18	11
1680	Treatment of acute promyelocytic leukaemia. 1996 , 9, 107-28	6
1679	Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid. 1996 , 92, 733-9	24
1678	The PML nuclear compartment and cancer. 1996 , 1288, M25-9	35
1677	All-trans retinoic acid and short-time, high-dose cytarabine in two children with acute promyelocytic leukemia. 1996 , 26, 254-7	1
1676	RNA polymerase II inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) causes erythroleukemic differentiation and transcriptional activation of erythroid genes. 1996 , 168, 105-13	12
1675	Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. 1996 , 15, 147-56	40
1674	Determination of retinoids by reversed-phase capillary liquid chromatography with amperometric electrochemical detection. 1996 , 677, 225-31	21
1673	Acrodermatitis continua of Hallopeau in a patient with myelodysplastic syndrome. 1996 , 134, 754-757	5
1672	Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. 1996 , 93, 542-50	57

1671	Tretinoin induces bone marrow collagenous fibrosis in acute promyelocytic leukaemia: new adverse, but reversible effect. 1996 , 93, 646-9	8
1670	Inhibition of growth and induction of apoptosis by all-trans retinoic acid in lymphoid cell lines transfected with the PML/RAR alpha fusion gene. 1996 , 93, 973-6	12
1669	Thrombocytosis in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment. 1996 , 95, 704-5	24
1668	Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. 1996 , 104, 167-72	34
1667	Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. 1996 , 15, 53-76	40
1666	Retinoids and apoptosis in cancer therapy. 1996 , 1, 11-24	6
1665	Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid. 1996 , 30, 55-60	15
1664	Topical retinoids and cutaneous biology. 1996 , 21, 1-10	17
1663	Plasminogen activation on tumor cell surface and its involvement in human leukemia. 1996 , 69, 101-33	14
1662	Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. 1996 , 10, 196-207	255
1661	Variant and masked translocations in acute promyelocytic leukemia. 1996 , 22, 221-8	32
1660	An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. 1996 , 271, 14412-20	314
1659	The architectural organization of nuclear metabolism. 1995 , 162A, 67-123	118
1658	Modulation of the anchorage-independent phenotype of human lung fibroblasts obtained from fibrotic tissue following culture with retinoid and corticosteroid. 1996 , 22, 231-44	7
1657	Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. 1996 , 271, 11557-62	60
1656	Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. 1996 , 271, 31723-8	257
1655	Selective suppression of nuclear retinoic acid receptor beta gene expression in human pancreatic carcinomas. 1996 , 8, 445-51	3
1654	Cancer in children. Introduction. 1996 , 52, 671-81	2

1653	Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. 1996 , 23, 493-503	22
1652	Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. 1996 , 20, 435-9	66
1651	Retinoic acid syndrome: pulmonary computed tomography (CT) findings. 1996 , 23, 113-7	18
1650	Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. 1996 , 23, 539-43	18
1649	The biologic function of PML and its role in acute promyelocytic leukemia. 1996 , 23, 277-85	20
1648	All-trans-retinoic acid and pseudotumor cerebri. 1996 , 23, 437-42	54
1647	Drug Resistance. 1996 ,	3
1646	The tobacco settlement. 1997 , 337, 1082-3	6
1645	Differentiation therapy for acute promyelocytic leukemia. 1997 , 337, 1076-7	36
1644	Emergency contraception--expanding opportunities for primary prevention. 1997 , 337, 1078-9	32
1643	Retinoic acid receptors alpha, beta and gamma, and cellular retinol binding protein-I expression in breast fibrocystic disease and cancer. 1997 , 137, 410-4	21
1642	Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid-resistant human breast cancer cells. 1997 , 272, 17921-8	48
1641	Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. 1997 , 272, 22447-55	152
1640	Life-and-death decisions influenced by retinoids. 1997 , 35, 1-46	15
1639	Synergistic induction of HL60 cell differentiation by ketoconazole and 1-desoxy analogues of vitamin D3. 1997 , 89, 1199-206	32
1638	Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. 1997 , 8, 518-21	20
1637	The genetics of dilated cardiomyopathy--emerging clues to the puzzle. 1997 , 337, 1080-1	55
1636	N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. 1997 , 89, 1179-81	11

1635	Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. 1997 , 17, 4859-69	120
1634	Tretinoin tocoferil as a possible differentiation-inducing agent against myelomonocytic leukemia. 1997 , 26, 43-8	13
1633	Calcitriol and isotretinoin combined therapy for precancerous and cancerous skin lesions. 1997 , 8, 5-10	5
1632	Retinoid resistance in leukemic cells. 1997 , 25, 427-34	24
1631	Tumour stem cells. 1997 , 363-399	21
1630	Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. 1997 , 139, 1621-34	295
1629	Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. 1997 , 94, 5826-30	191
1628	Induction of Apoptosis in Human Leukaemia Cells is Differentially Regulated by Vitamin D Derivatives and Retinoids. 1997 , 2, 289-301	3
1627	Retinoid Receptors and Cancer. 1997 , 219-230	
1626	Plasma cell dyscrasias. 1997 , 64, 219-81	2
1625	The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. 1997 , 8, 1273-5	20
1624	Clinical pharmacokinetics of tretinoin. 1997 , 32, 382-402	48
1623	The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. 1997 , 54, 625-34	44
1622	Oncogenic transcription factors in the human acute leukemias. 1997 , 278, 1059-64	999
1621	All-trans-retinoic acid in acute promyelocytic leukemia. 1997 , 337, 1021-8	895
1620	Action mechanism of retinoid-synergistic dibenzodiazepines. 1997 , 233, 121-5	35
1619	DIF-1, putative morphogen of D. discoideum, suppresses cell growth and promotes retinoic acid-induced cell differentiation in HL-60. 1997 , 236, 418-22	64
1618	Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine. 1997 , 238, 100-6	15

1617	A novel interferon-inducible gene expressed during myeloid differentiation. 1997 , 23, 337-49		21
1616	Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. 1997 , 232, 376-87		43
1615	Altered sensitivity to retinoid-induced apoptosis associated with changes in the subcellular distribution of Bcl-2. 1997 , 233, 281-7		27
1614	All-trans retinoic acid for the treatment of acute promyelocytic leukemia in pregnancy. 1997 , 89, 826-8		22
1613	Isochromosome for derivative 17q in acute promyelocytic leukemia: Evidence for two copies of PML-RARA and favorable response to all-trans-retinoic acid therapy. 1997 , 18, 151-153		5
1612	The acute promyelocytic leukemia PML-RAR alpha protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice. <i>Oncogene</i> , 1997 , 14, 1547-54	9.2	27
1611	Dietary phytoestrogens. 1997 , 17, 353-81		731
1610	Nuclear dots: actors on many stages. 1997 , 198, 307-31		129
1609	New strategies for the treatment of acute promyelocytic leukaemia. 1997 , 242, 23-27		5
1608	All-Trans Retinoic Acid [Progress in Treatment of Acute Promyelocytic Leukemia. 1997 , 20, 122-124		
1607	Lung Cancer Chemoprevention and Management of Carcinoma in situ. 1997 , 29, 1-20		3
1606	Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML). <i>Blood</i> , 1997 , 90, 4046-4053	2.2	113
1605	Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH) ₂ Vitamin D ₃ , and Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1997 , 90, 4578-4587	2.2	69
1604	Retinoid Induced Apoptosis in Leukemia Cells Through a Retinoic Acid Nuclear Receptor-Independent Pathway. <i>Blood</i> , 1997 , 89, 4470-4479	2.2	126
1603	Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RAR Under Control of Cathepsin G Regulatory Sequences. <i>Blood</i> , 1997 , 89, 376-387	2.2	320
1602	Altered Expression of the Retinoblastoma Tumor-Suppressor Gene in Leukemic Cell Lines Inhibits Induction of Differentiation But Not G1-Accumulation. <i>Blood</i> , 1997 , 89, 2938-2950	2.2	31
1601	Treatment With a New Synthetic Retinoid, Am80, of Acute Promyelocytic Leukemia Relapsed From Complete Remission Induced by All-trans Retinoic Acid. <i>Blood</i> , 1997 , 90, 967-973	2.2	162
1600	An Allelic Association Implicates Myeloperoxidase in the Etiology of Acute Promyelocytic Leukemia. <i>Blood</i> , 1997 , 90, 2730-2737	2.2	141

1599	Adult acute leukaemia--a retrospective study of 66 consecutive patients. 1997 , 27, 301-6		3
1598	Effects of all-trans retinoic acid on choriocarcinoma cells in vitro. 1997 , 23, 125-32		2
1597	The present role of bone marrow and stem cell transplantation in the therapy of children with acute leukemia. 1997 , 824, 38-64		8
1596	The war on cancer: a review. 1997 , 833, 137-46		41
1595	Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. 1997 , 11, 175-80		47
1594	Expression of NADPH oxidase is induced by all-trans retinoic acid but not by phorbol myristate acetate and 1,25 dihydroxyvitamin D3 in the human promyelocytic cell line NB4. 1997 , 11, 2131-6		15
1593	Induction of thrombospondin-1 by all-trans retinoic acid modulates growth and differentiation of HL-60 myeloid leukemia cells. 1997 , 11, 2137-42		10
1592	Frequent association of alternative splicing of NER, a nuclear hormone receptor gene in cancer tissues. <i>Oncogene</i> , 1997 , 14, 617-21	9.2	15
1591	The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain. <i>Oncogene</i> , 1997 , 14, 1067-74	9.2	58
1590	JEM-1, a novel gene encoding a leucine-zipper nuclear factor upregulated during retinoid-induced maturation of NB4 promyelocytic leukaemia. <i>Oncogene</i> , 1997 , 14, 1563-70	9.2	24
1589	Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers. <i>Oncogene</i> , 1997 , 14, 2613-8	9.2	15
1588	Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. 1997 , 3, 686-90		82
1587	All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. 1997 , 75, 1284-90		11
1586	Growth inhibition of cultured human gastric cancer cells by 9-cis-retinoic acid with induction of cdk inhibitor Waf1/Cip1/Sdi1/p21 protein. 1997 , 61, 313-20		27
1585	Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. 1997 , 61, 321-31		38
1584	Retinol (vitamin A) and retinal-binding protein serum levels in children with cancer at onset. 1997 , 13, 17-20		9
1583	Differentiation, differentiation/gene therapy and cancer. 1997 , 73, 51-65		40
1582	Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. 1997 , 76, 141-9		68

1581	Characterization of the cholinergic neuronal differentiation of the human neuroblastoma cell line LA-N-5 after treatment with retinoic acid. 1997 , 102, 53-67	31
1580	Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: modulating effects of dihydroxylated vitamin D3, alpha interferon and 'stem cell factor'. 1997 , 21, 51-8	7
1579	Acute promyelocytic leukemia--from the bench to the bedside. 1997 , 21, 295-7	1
1578	Reversibility of monocytic differentiation of HL-60 cells by 1alpha,25 dihydroxyvitamin D3. 1997 , 21, 217-24	2
1577	CB1093, a novel vitamin D analog; effects on differentiation and clonal growth on HL-60 and de novo leukemia cells. 1997 , 21, 321-6	13
1576	Granulocyte-colony stimulating factor induces differentiation and apoptosis of CD2, CD7 positive hybrid leukemia cells in vivo and ex vivo. 1997 , 21, 735-41	8
1575	The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. 1997 , 21, 985-95	24
1574	All-trans retinoic acid induces apoptosis in acute myeloblastic leukaemia cells. 1997 , 2, 319-29	10
1573	Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. 1997 , 40, 3567-83	55
1572	Influence of retinoic acid on the differentiation pathway of T cells in the thymus. 1997 , 181, 153-62	13
1571	All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. 1997 , 34, 193-200	40
1570	TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. 1998 , 16, 323-31	13
1569	Transcriptional regulation during myelopoiesis. 1997 , 24, 157-68	64
1568	Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia. 1997 , 14, 65-72	5
1567	Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. 1997 , 75, 195-200	13
1566	Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. 1997 , 39, 291-9	55
1565	Chemoprevention of human cancer: biology and therapy. 1997 , 25, 139-74	54
1564	Adult acute leukemia. 1997 , 21, 1-64	22

1563	Liposomal 1,25 (OH) ₂ vitamin D ₃ compounds block proliferation and induce differentiation in myelomonocytic leukaemia cells. 1997 , 98, 186-94	6
1562	Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. 1997 , 97, 137-40	11
1561	Effects of all-trans-retinoic acid on superoxide generation in intact neutrophils and a cell-free system. 1997 , 97, 300-5	26
1560	The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody. 1997 , 99, 597-604	24
1559	Myeloid differentiation is impaired in transgenic mice with targeted expression of a dominant negative form of retinoid X receptor beta. 1997 , 96, 19-30	13
1558	Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. 1997 , 15, 13-7	2
1557	Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia. 1997 , 15, 209-17	9
1556	Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. 1997 , 32, 115-21	37
1555	Retinoic acid abolishes the calcitonin gene-related peptide autocrine system in F9 teratocarcinoma cells. 1997 , 64, 447-457	3
1554	Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. 1997 , 67, 13-23	35
1553	Differentiation therapy in acute promyelocytic leukemia: European experience. 1997 , 173, 285-7	8
1552	Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia. 1997 , 70, 496-7	12
1551	Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines. 1997 , 72, 906-11	14
1550	Fatal systemic inflammatory response syndrome following early bilateral femoral nailing. 1998 , 24, 641-2	50
1549	Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. 1998 , 17, 61-70	544
1548	Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective study. 1998 , 28, 190-6	1
1547	Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia. 1998 , 12, 1503-6	13
1546	A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. 1998 , 12, 1829-33	38

1545	Expression patterns of the JEM-1 gene in normal and tumor cells: ubiquity contrasting with a faint, but retinoid-induced, mRNA expression in promyelocytic NB4 cells. 1998 , 12, 1733-40		7
1544	Acute promyelocytic leukemia: a curable disease. 1998 , 12, 1866-80		102
1543	Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. <i>Oncogene</i> , 1998 , 16, 3471-80	9.2	33
1542	Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. <i>Oncogene</i> , 1998 , 17, 1759-68	9.2	46
1541	Establishment of a retinoic acid-resistant human acute promyelocytic leukaemia (APL) model in human granulocyte-macrophage colony-stimulating factor (hGM-CSF) transgenic severe combined immunodeficiency (SCID) mice. 1998 , 78, 878-84		10
1540	Expression of beta1-integrins and pseudo-immunoglobulins on acute promyelocytic leukemia cells and its modifications during in vitro differentiation. 1998 , 22, 61-8		7
1539	Induction of differentiation and apoptosis by dithizone in human myeloid leukemia cell lines. 1998 , 22, 405-12		25
1538	A novel retinoic acid receptor (RAR)-selective antagonist inhibits differentiation and apoptosis of HL-60 cells: implications of RARalpha-mediated signals in myeloid leukemic cells. 1998 , 22, 517-25		13
1537	Overgrowth of a leukemic culture by a minor CD34+ population. 1998 , 22, 549-56		1
1536	Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. 1998 , 22, 611-8		29
1535	Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. 1998 , 22, 1113-22		13
1534	Retinoic acid differentially regulates interleukin-1beta and interleukin-1 receptor antagonist production by human alveolar macrophages. 1998 , 22, 1057-61		21
1533	p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. 1998 , 34, 529-37		34
1532	Chemoprevention in head and neck cancer: basic science and clinical application. 1998 , 8, 292-301		6
1531	Chronic alcohol intake reduces retinoic acid concentration and enhances AP-1 (c-Jun and c-Fos) expression in rat liver. 1998 , 28, 744-50		117
1530	The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. 1998 , 83, 1471-82		119
1529	Acute promyelocytic leukemia (APL) with an unusual cytogenetic presentation. 1998 , 30, 69-72		
1528	High retinoid X receptor expression in JEG-3 choriocarcinoma cells: involvement in cell function modulation by retinoids. 1998 , 176, 595-601		11

1527	In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes. 1998 , 22, 241-50	24
1526	Successful treatment of acute promyelocytic leukemia using all-trans retinoic acid and erythropoietin in a Jehovah's Witness boy. 1998 , 76, 43-4	10
1525	Effect of 5-aza-2'-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. 1998 , 41, 275-80	12
1524	Acute respiratory distress syndrome due to all-trans retinoic acid. 1998 , 24, 642	8
1523	Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCaT cells. 1998 , 111, 434-9	40
1522	Gamma-irradiation does not impair ATRA-induced maturation of myeloid leukaemic cells: implication for combined radiation and differentiation therapy. 1998 , 103, 79-86	3
1521	All-trans-retinoic acid up-regulates CD38 but not c-Kit antigens on human marrow CD34+ cells without recruitment into cell cycle. 1998 , 103, 343-50	9
1520	Ultrastructural characteristics and lysozyme content in hypergranular and variant type of acute promyelocytic leukaemia. 1998 , 103, 729-39	10
1519	Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. 1998 , 103, 721-8	39
1518	Ultrastructural characteristics and lysozyme content in hypergranular and vibrant type of acute promyelocytic leukaemia. 1998 , 102, 729-739	48
1517	Arsenic trioxide inhibits growth of human T- cell leukaemia virus type I infected T- cell lines more effectively than retinoic acids. 1998 , 102, 721-728	
1516	A HPLC method for the determination of 9-cis retinoic acid (ALRT1057) and its 4-oxo metabolite in human plasma. 1998 , 16, 1013-9	6
1515	Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form. 1998 , 134, 121-8	27
1514	Systemic treatment of neoplastic conditions with retinoids. 1998 , 39, S108-13	4
1513	The synergistic effect of simultaneous addition of retinoic acid and vitamin D3 on the in-vitro differentiation of human promyelocytic leukemia cell lines could be efficiently transposed in vivo. 1998 , 50, 253-7	3
1512	Advances in the management of cutaneous T-cell lymphoma. 1998 , 16, 301-11	13
1511	Retinoid related molecules: new promises against lung and breast cancer. 1998 , 7, 601-6	9
1510	Induction of differentiation in human promyelocytic leukemia cell line HL60 by a new type of polyenes, falconensone A and its derivatives. 1998 , 360, 113-20	7

1509	Oncoprotein v-Myb and retinoic acid receptor alpha are mutual antagonists. 1998 , 24, 239-50	5
1508	Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates with retinoidal activity. 1998 , 41, 3062-77	23
1507	Retinoic acid syndrome. Recognition, prevention and management. 1998 , 18, 273-9	25
1506	Inhibitors of lipoxygenase metabolism exert synergistic effects with retinoic acid on differentiation of human leukemia HL-60 cells. 1998 , 350, 273-84	54
1505	Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. 1998 , 339, 1341-8	1037
1504	The Human Leukemia Cell Line HL-60 as a Cell Culture Model To Study Neutrophil Functions and Inflammatory Cell Responses. 1998 , 264-297	15
1503	Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. 1998 , 90, 86-8	37
1502	Regulation of IRF and STAT gene expression by retinoic acid. 1998 , 30, 63-71	38
1501	All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia. 1998 , 15, 243-8	21
1500	RT-PCR in diagnosis and disease monitoring of acute promyelocytic leukemia (APL). 1998 , 89, 333-58	3
1499	Nonisotopic in situ hybridization for the detection of nuclear retinoid receptor transcripts in tissue sections. 1998 , 89, 233-46	3
1498	Treatment of disseminated intravascular coagulation (DIC) with all-trans retinoic acid in an endotoxin-induced rat model. 1998 , 24, 227-31	10
1497	Effects of DIF-1, an Anti-Tumor Agent Isolated from Dictyostelium discoideum, on Rat Gastric Mucosal RGM-1 and Leptomeningeal Cells. 1998 , 15, 713-721	4
1496	Chemoprevention of colorectal cancer. 1998 , 43, 578-85	44
1495	Pentoxifylline synergizes with all-trans retinoic acid to induce differentiation of HL-60 myelocytic cells, but suppresses tRA-augmented clonal growth of normal CFU-GM. 1998 , 99, 191-9	8
1494	Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. 1998 , 90, 1621-5	461
1493	All-trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. 1998 , 77, 186-91	70
1492	Effects of all-trans retinoic acid and interferon alpha in peripheral neuroectodermal tumor cell cultures and xenografts. 1998 , 13, 943-9	0

1491	CD95 predicts responsiveness to tretinoin in acute promyelocytic leukemia. 1998 , 1, 207-11		1
1490	The NGFI-B subfamily of the nuclear receptor superfamily (review). 1998 , 12, 1237-43		33
1489	Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. 1998 , 158, 1302-5		77
1488	Acute promyelocytic leukemia in children. 1998 , 15, 203-6		2
1487	Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. 1998 , 77, 739-44		21
1486	The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia. 1998 , 31, 491-9		11
1485	Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. 1998 , 68, 1426S-1430S		90
1484	Molecular genetics of childhood leukemias. 1998 , 20, 1-11		51
1483	Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. 1998 , 30, 11-22		32
1482	Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. 1998 , 31, 441-51		29
1481	Physical interaction between retinoic acid receptor and the oncoprotein myb inhibits retinoic acid-dependent transactivation. 1998 , 95, 5539-44		27
1480	Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells. 1998 , 30, 361-6		4
1479	Cancer Procoagulant and Tissue Factor Are Differently Modulated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells. <i>Blood</i> , 1998 , 92, 143-151	2.2	99
1478	Phosphorylation of BCL-2 After Exposure of Human Leukemic Cells to Retinoic Acid. <i>Blood</i> , 1998 , 92, 1768-1775	2.2	58
1477	Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1998 , 92, 2712-2718	2.2	278
1476	Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. <i>Blood</i> , 1998 , 91, 4300-4310	2.2	159
1475	Restoration of Retinoid Sensitivity by MDR1 Ribozymes in Retinoic AcidResistant Myeloid Leukemic Cells. <i>Blood</i> , 1998 , 91, 2452-2458	2.2	23
1474	Acute Promyelocytic Leukemia: Relieving Repression Induces Remission. <i>Blood</i> , 1998 , 91, 2631-2633	2.2	46

1473	Trivalent Antimonials Induce Degradation of the PML-RAR α Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells. <i>Blood</i> , 1998 , 92, 4308-4316	2.2	77
1472	Mutations in the E-Domain of RAR α Portion of the PML/RAR α Chimeric Gene May Confer Clinical Resistance to All-trans Retinoic Acid in Acute Promyelocytic Leukemia. <i>Blood</i> , 1998 , 92, 374-382	2.2	91
1471	Impaired Granulocytic Differentiation In Vitro in Hematopoietic Cells Lacking Retinoic Acid Receptors α and β . <i>Blood</i> , 1998 , 92, 607-615	2.2	94
1470	Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RAR α Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy. <i>Blood</i> , 1998 , 92, 1172-1183	2.2	111
1469	Effect of all-trans retinoic acid on newly diagnosed acute promyelocytic leukemia patients: results of a Brazilian center. 1998 , 31, 1537-43		16
1468	Adult acute myeloid leukaemia: update on treatment. 1999 , 170, 39-43		15
1467	Deconstructing a Disease: RAR α , Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 93, 3167-3215	2.2	901
1466	Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial. <i>Blood</i> , 1999 , 93, 4131-4143	2.2	347
1465	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. <i>Blood</i> , 1999 , 93, 1308-1318	2.2	174
1464	Effects of Novel RAR- and RXR-Selective Retinoids on Myeloid Leukemic Proliferation and Differentiation In Vitro. <i>Blood</i> , 1999 , 93, 2057-2066	2.2	40
1463	1,25-Dihydroxyvitamin D ₃ Induces Differentiation of a Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated With Expression of p21WAF1/CIP1 and p27KIP1. <i>Blood</i> , 1999 , 93, 2225-2233	2.2	81
1462	Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 12-22	2.2	173
1461	Complete Remission of t(11;17) Positive Acute Promyelocytic Leukemia Induced by All-trans Retinoic Acid and Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1999 , 94, 39-45	2.2	71
1460	Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients. <i>Blood</i> , 1999 , 94, 3315-3324	2.2	518
1459	Chromatin Remodeling and Leukemia: New Therapeutic Paradigms. <i>Blood</i> , 1999 , 94, 417-428	2.2	158
1458	All-Trans Retinoic Acid Delays the Differentiation of Primitive Hematopoietic Precursors (lin ⁻ kit+Sca-1+) While Enhancing the Terminal Maturation of Committed Granulocyte/Monocyte Progenitors. <i>Blood</i> , 1999 , 94, 483-495	2.2	97
1457	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 1192-1200	2.2	606
1456	CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate Into Dendritic Cells. <i>Blood</i> , 1999 , 94, 2048-2055	2.2	114

1455	Molecular Remissions Induced by Liposomal-Encapsulated All-Trans Retinoic Acid in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 2230-2235	2.2	95
1454	Suppression of rat liver tumorigenesis by 25-hydroxycholesterol and all-trans retinoic acid: differentiation therapy for hepatocellular carcinoma. 1999 , 15, 565-9		2
1453	A novel retinoic acid-resistant acute promyelocytic leukemia model in vitro and in vivo (review). 1999 , 4, 359-64		4
1452	Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. 1999 , 35, 483-9		12
1451	The thrombophilic state in acute promyelocytic leukemia. 1999 , 25, 209-15		19
1450	The molecular biology of acute promyelocytic leukemia. 1999 , 99, 75-124		37
1449	Annexin II and bleeding in acute promyelocytic leukemia. 1999 , 340, 994-1004		319
1448	All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. 1999 , 33, 267-80		16
1447	Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. 1999 , 96, 14807-12		299
1446	Sublingual administration of all-trans-retinoic acid to a comatose patient with acute promyelocytic leukemia. 1999 , 33, 503-5		4
1445	A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. 1999 , 96, 4592-7		635
1444	Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia. 1999 , 34, 261-71		11
1443	Retinoid-mediated signaling pathways in CD38 antigen expression in myeloid leukemia cells. 1999 , 32, 441-9		16
1442	RAR-Selective Ligands: Receptor Subtype and Function Selectivity. 1999 , 185-213		7
1441	Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. 1999 , 189, 1043-52		274
1440	Acute progranulocytic leukaemia: a model for molecular medicine. 1999 , 3, 135-150		1
1439	Differentiation of leukemic cells induced by short-course high-dose methylprednisolone in children with different subtypes of acute myeloblastic leukemia. 1999 , 33, 573-80		17
1438	Myelodysplasia. 1999 , 340, 1649-60		411

1437	Novel retinoids with receptor selectivity and functional selectivity. 1999 , 140 Suppl 54, 12-7		44
1436	The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. 1999 , 106, 591-613		69
1435	Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience. 1999 , 29, 385-6		8
1434	Serum thrombopoietin and erythropoietin levels in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment. 1999 , 105, 382-387		7
1433	Modulation of apoptosis of proliferating and differentiating HL-60 cells by protein kinase inhibitors: suppression of PKC or PKA differently affects cell differentiation and apoptosis. 1999 , 6, 698-709		26
1432	Atypical response to all-trans retinoic acid in a der(5)t(5;17) acute promyelocytic leukemia. 1999 , 13, 862-8		5
1431	Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. 1999 , 13, 1062-70		57
1430	Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. 1999 , 13, 1167-74		52
1429	JEM-1, a novel nuclear co-factor: localisation and functional interaction with AP-1. 1999 , 13, 1982-92		15
1428	Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. <i>Oncogene</i> , 1999 , 18, 1113-8	9.2	92
1427	Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis. <i>Oncogene</i> , 1999 , 18, 3529-40	9.2	22
1426	Acute promyelocytic leukemia: from treatment to genetics and back. <i>Oncogene</i> , 1999 , 18, 5261-7	9.2	21
1425	Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid. 1999 , 79, 101-7		17
1424	Retinoids: present role and future potential. 1999 , 80, 1-8		190
1423	Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. 1999 , 24, 345-8		15
1422	RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. 1999 , 18, 7011-8		97
1421	Acute promyelocytic leukaemia: a retrospective analysis of patients treated at St. Bartholomew's Hospital 1969-1995. 1999 , 78, 131-7		0
1420	Variation of serum G-CSF level in APL treated with all-trans retinoic acid. 1999 , 11, 131-135		2

1419	Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia. 1999 , 16, 119-28	4
1418	Relationship between G-CSF and hyperleukocytosis in patients with APL after treatment with all-trans retinoic acid. 1999 , 11, 249-252	2
1417	Molecular genetics of acute promyelocytic leukemia. 1999 , 15, 179-84	99
1416	Acridones as inducers of HL-60 cell differentiation. 1999 , 23, 263-9	27
1415	A proposal regarding the mechanism which underlies lineage choice during hematopoietic differentiation. 1999 , 23, 685-94	12
1414	Detection of apoptosis in acute promyelocytic leukemia cells in vivo during differentiation-induction with all-trans retinoic acid in combination with chemotherapy. 1999 , 23, 827-32	8
1413	Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells. 1999 , 27, 642-53	35
1412	Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39. 1999 , 27, 1322-9	21
1411	Neutrophil maturation and the role of retinoic acid. 1999 , 27, 1355-67	50
1410	Modulation of a calcium/calmodulin-dependent protein kinase cascade by retinoic acid during neutrophil maturation. 1999 , 27, 1682-90	14
1409	Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. 1999 , 32, 143-54	75
1408	Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. 1999 , 82, 286-92	53
1407	Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone. 1999 , 60, 87-93	13
1406	All-trans retinoic acid-induced multiple mononeuropathies. 1999 , 60, 311	7
1405	Soft drink abuse, malnutrition, and folic acid deficiency. 1999 , 60, 311-2	1
1404	Sex difference in myeloperoxidase activity of neutrophils. 1999 , 60, 312-3	11
1403	Case of hepatosplenic gammadelta T-cell lymphoma presenting with severe hypersplenism. 1999 , 60, 313-4	6
1402	New oral chemotherapeutic agents for lung cancer. 1999 , 58 Suppl 3, 57-69	10

1401	Oral chemotherapy agents in the treatment of leukaemia. 1999 , 58 Suppl 3, 109-18	3
1400	Retinoids. 1999 ,	11
1399	Induction of granulocytic differentiation in acute promyelocytic leukemia cells (HL-60) by 2-(allylthio) pyrazine. 1999 , 144, 1-8	6
1398	Hypophosphorylation of pRB and repression of cyclin D3 and cdc25A during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells. 1999 , 23, 901-7	8
1397	Transcriptional activation of the cyclin-dependent kinase inhibitor p21 by PML/RARalpha. 1999 , 1, 125-31	4
1396	Induction of cellular differentiation by retinoic acid in vitro. 1999 , 165, 190-202	181
1395	Potential of the acenocoumarol anticoagulant effect by acetaminophen. 1999 , 33, 506	8
1394	Preferential platination of an activated cellular promoter by cis-diamminedichloroplatinum. 1999 , 38, 12432-8	11
1393	Role of vitamin D3 receptor in the synergistic differentiation of WEHI-3B leukemia cells by vitamin D3 and retinoic acid. 1999 , 249, 279-90	16
1392	Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. 1999 , 263, 294-300	42
1391	1,25-Dihydroxyvitamin D3, recombinant human transforming growth factor-beta 1, and recombinant human bone morphogenetic protein-2 induce in vitro differentiation of canine osteosarcoma cells. 1999 , 61, 649-56	17
1390	Arsenic: a new place?. 1999 , 31, 81-2	1
1389	Diagnostic approaches to acute promyelocytic leukaemia. 1999 , 33, 53-63	9
1388	Retinoid X receptor suppresses transformation by the v-myb oncogene. 1999 , 66, 1039-48	8
1387	The potential application of ribozymes for the treatment of hematological disorders. 1999 , 66, 361-8	3
1386	Efficacy of all-trans retinoic acid for molecular relapse of acute promyelocytic leukemia during remission. 1999 , 6, 683-5	
1385	Retinoid X receptor (RXR) agonist-induced activation of dominant-negative RXR-retinoic acid receptor alpha403 heterodimers is developmentally regulated during myeloid differentiation. 1999 , 19, 3372-82	32
1384	PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. 1999 , 19, 5170-8	90

1383	Extramedullary disease in acute promyelocytic leukemia. 1999 , 33, 219-29	69
1382	A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG). 1999 , 34, 501-10	6
1381	New molecular targets for cancer chemotherapy. 1999 , 38, 186-90	
1380	Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. 2000 , 38, 195-8	26
1379	In vitro retinoid-induced growth inhibition and morphologic differentiation of canine osteosarcoma cells. 2000 , 61, 69-73	16
1378	Effect of all-trans and 9-cis retinoic acid on growth and metastasis of xenotransplanted canine osteosarcoma cells in athymic mice. 2000 , 61, 1241-4	7
1377	All-trans-retinoic acid-induced myositis: a description of two patients. 2000 , 63, 94-8	22
1376	Two new 3? PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. 2000 , 27, 35-43	18
1375	Cycloprodigiosin hydrochloride, H(+)/CL(-) symporter, induces apoptosis and differentiation in HL-60 cells. 2000 , 88, 121-8	50
1374	Differential display as an approach to study differentiation and differentiation therapy in AML. 2000 , 18, 129-140	3
1373	Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. 2000 , 108, 696-702	75
1372	Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. 2000 , 108, 689-95	97
1371	Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia. 2000 , 110, 552-62	22
1370	Scrotal ulceration during all-trans retinoic (ATRA) therapy for acute promyelocytic leukaemia. 2000 , 22, 171-4	23
1369	Interferon may reduce minimal residual disease of acute promyelocytic leukemia. 2000 , 14, 1153	
1368	The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. 2000 , 14, 77-83	29
1367	Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. 2000 , 14, 431-8	56
1366	A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. 2000 , 14, 255-61	66

1365	Differentiation therapy in acute myelogenous leukemia (non-APL). 2000 , 14, 491-6		59
1364	Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. <i>Acute promyelocytic leukemia</i> . 2000 , 14, 1006-13		88
1363	Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. 2000 , 14, 1362-70		131
1362	Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. 2000 , 14, 1371-7		137
1361	Defect in the regulation of 4E-BP1 and 2, two repressors of translation initiation, in the retinoid acid resistant cell lines, NB4-R1 and NB4-R2. 2000 , 14, 1909-14		15
1360	Modifications in phospholipase D activity and isoform expression occur upon maturation and differentiation in vivo and in vitro in human myeloid cells. 2000 , 14, 2118-27		27
1359	Susceptibility to apoptosis is restored in human leukemia HCW-2 cells following induction and stabilization of the apoptotic effector Bak. <i>Oncogene</i> , 2000 , 19, 4108-16	9.2	3
1358	Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. 2000 , 91, 1169-76		24
1357	Clinical spectrum of extramedullary acute promyelocytic leukemia. 2000 , 64, 201-3		9
1356	The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. 2000 , 64, 211-8		13
1355	Vitamin A and cancer. 2000 , 16, 573-6		28
1354	Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. 2000 , 16, 1084-9		126
1353	PPARgamma: observations in the hematopoietic system. 2000 , 62, 45-73		46
1352	High relative proportion of acute promyelocytic leukemia in children: experience of a multicenter study in Cuba. 2000 , 24, 739-40		11
1351	Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60). 2000 , 24, 543-8		1
1350	Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. 2000 , 24, 1-9		21
1349	Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML. 2000 , 24, 19-25		15
1348	Erythroblastic and/or megakaryocytic dysplasia in de novo acute myeloid leukemias M0-M5 show relation to myelodysplastic syndromes and delimit two main categories. 2000 , 24, 207-15		9

1347	The promyelocytic (PML) nuclear compartment and transcription control. 2000 , 60, 1197-201		29
1346	Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. 2000 , 82, 452-8		27
1345	Accelerated and blastic phase of chronic myeloid leukemia. 2000 , 1, 51-62		9
1344	Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. 2000 , 2, 519-23		23
1343	Enhanced migration of the acute promyelocytic leukemia cell line NB4 under in vitro conditions during short-term all-trans-retinoic acid treatment. 2000 , 126, 33-40		25
1342	Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. 2000 , 25, 275-84		52
1341	Leukemia initiated by PMLRAR α the PML domain plays a critical role while retinoic acid α mediated transactivation is dispensable. <i>Blood</i> , 2000 , 95, 1541-1550	2.2	86
1340	HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. <i>Blood</i> , 2000 , 96, 3553-3559	2.2	47
1339	Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid α treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation. <i>Blood</i> , 2000 , 96, 2262-2268	2.2	20
1338	Blood: New designs for a new millennium. <i>Blood</i> , 2000 , 95, 1-6	2.2	11
1337	Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid α sensitive and α resistant acute promyelocytic leukemia cells. <i>Blood</i> , 2000 , 96, 2233-2239	2.2	21
1336	The Role of Retinoic Acid Receptors in Myeloid Differentiation. 149-161		
1335	Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. 2000 , 18, 2620-5		160
1334	Minimal Residual Disease in Acute Promyelocytic Leukemia. 2000 , 20, 105-117		1
1333	Acute Promyelocytic Leukemia: From Morphology to Molecular Lesions. 2000 , 20, 83-103		11
1332	Transcriptional Targets of the Vitamin D3 Receptor During Myeloid Cell Differentiation. 163-180		1
1331	Antibody therapy of acute myelogenous leukemia. 2000 , 15, 319-26		14
1330	Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPAR γ agonists. 2000 , 83, 1394-400		192

1329	Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule. 2000 , 17, 155-62	9
1328	Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. 2000 , 114, 786-92	25
1327	Anti-tumor effects of 25-hydroxycholesterol and low-dose recombinant tumor necrosis factor-alpha on rat liver tumorigenesis: modulated differentiation therapy for hepatocellular carcinoma. 2000 , 16, 1029-33	1
1326	Retinoids in chemoprevention and differentiation therapy. 2000 , 21, 1271-1279	215
1325	Establishment of a myeloid cell line, YM711, characterized by retinoid resistance. 2000 , 39, 373-83	1
1324	Thyroid hormone regulation of apoptosis induced by retinoic acid in promyeloleukemic HL-60 cells: studies with retinoic acid receptor-specific and retinoid x receptor-specific ligands. 2000 , 10, 1023-34	13
1323	Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. 2000 , 38, 283-93	34
1322	Targeted therapies for the myeloid leukaemias. 2000 , 9, 1197-205	12
1321	Studies on structure-activity relationships of retinoic acid receptor ligands by means of molecular modeling. 2000 , 59, 159-215	3
1320	Retinoids and demethylating agents- looking for partners. 2000 , 92, 780-1	15
1319	A NOVEL APPROACH TO TREATMENT WITH HIGH-DOSE STEROID AS A DIFFERENTIATION INDUCER IN CHILDREN WITH ACUTE MYELOBLASTIC LEUKEMIA. 2000 , 19, 251-259	
1318	Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. 2000 , 277, 179-85	56
1317	The effects of RARalpha and RXRalpha proteins on growth, viability, and differentiation of v-myb-transformed monoblasts. 2000 , 26, 395-406	4
1316	Retinoic acid-induced blr1 expression promotes ERK2 activation and cell differentiation in HL-60 cells. 2000 , 254, 287-98	31
1315	Genomic organization of the JEM-1 (BLZF1) gene on human chromosome 1q24: molecular cloning and analysis of its promoter region. 2000 , 69, 380-90	5
1314	Transcription therapy for acute promyelocytic leukaemia. 2000 , 9, 329-46	4
1313	Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. 2000 , 151, 63-70	14
1312	Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant <i>Saccharomyces cerevisiae</i> . 2000 , 45, 293-301	55

1311	Differentiation induction of canine osteosarcoma cell lines by retinoids. 2000 , 68, 57-62	7
1310	Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. 2000 , 5, 821-30	205
1309	Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. 2000 , 36, 2007-17	24
1308	The molecular biology of cancer. 2000 , 21, 167-223	290
1307	White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice. 2000 , 355, 1447-53	4
1306	Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions. 2000 , 28, 1441-50	22
1305	A NOVEL APPROACH TO TREATMENT WITH HIGH-DOSE STEROID AS A DIFFERENTIATION INDUCER IN CHILDREN WITH ACUTE MYELOBLASTIC LEUKEMIA. 2000 , 19, 251-259	1
1304	Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro. 2000 , 39, 173-84	9
1303	Retinoic acid receptor alpha (RARalpha) Mutations in Human Leukemia. 2000 , 39, 271-82	9
1302	Vidarabine and 2-deoxycoformycin as antileukemic agents against monocytic leukemia. 2000 , 39, 57-66	8
1301	Differentiation-inducing effects of small fruit juices on HL-60 leukemic cells. 2000 , 48, 3177-82	14
1300	Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. 2000 , 40, 167-78	71
1299	A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. 2000 , 83, 1124-7	50
1298	Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). 2000 , 1 Suppl 1, S41-4	26
1297	Molecular genetics of acute myeloid leukaemia. 2001 , 14, 49-64	109
1296	Treatment of acute promyelocytic leukaemia. 2001 , 14, 153-74	57
1295	Differentiation versus maturation of neoplastic hematopoietic cells: an important distinction. 2001 , 27, 649-52	4
1294	Identification of PML oncogenic domains (PODs) in human megakaryocytes. 2001 , 271, 277-85	6

1293	The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines. 2001 , 164, 15-23	18
1292	All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. 2001 , 38, 13-25	92
1291	Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. 2001 , 38, 26-36	2
1290	Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein. 2001 , 38, 37-41	18
1289	Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. 2001 , 102, 197-204	22
1288	Targeted therapies for high-risk acute myeloid leukemia. 2001 , 15, 677-701, viii-ix	4
1287	Retinoid therapy of childhood cancer. 2001 , 15, 867-910	90
1286	Leucemias agudas mieloblásticas. Clasificación. Etiopatogenia. Características citológicas, inmunofenotípicas y moleculares. 2001 , 8, 2881-2889	
1285	Transcription factors that regulate growth and differentiation of myeloid cells. 2001 , 20, 83-105	84
1284	Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture. 2001 , 64, 1509-13	19
1283	Nucleic acids. 2001 , 271-291	2
1282	Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques. 2001 , 34, 735-43	17
1281	Expression and Anticoagulant Function of the Endothelial Cell Protein C Receptor (EPCR) in Cancer Cell Lines. 2001 , 85, 356-361	51
1280	Therapy of acute myeloid leukemia. 2001 , 8, 62-78	21
1279	Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. 2001 , 19, 2033-40	97
1278	All-trans retinoic acid is partially effective against lipopolysaccharide-induced but not against tissue-factor-induced disseminated intravascular coagulation in rat models. 2001 , 12, 301-6	5
1277	Meeting report of the 2000 International Congress of Pediatric Hematology/Oncology: Shanghai Children's Medical Center, Shanghai, People's Republic of China, October 18-20, 2000. 2001 , 23, 533-47	
1276	Monitoring of minimal residual disease in children with acute promyelocytic leukemia by RT-PCR detecting PML/RARalpha chimeric gene: a retrospective study of clinical feasibility. 2001 , 193, 127-39	5

1275	Characterization of nuclear factors that bind to the human thymidylate synthase gene in HL-60 cells differentiated by all-trans retinoic acid treatment. 2001 , 24, 1351-5		3
1274	In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. <i>Blood</i> , 2001 , 98, 2862-4	2.2	36
1273	Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. <i>Blood</i> , 2001 , 97, 264-9	2.2	186
1272	Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. <i>Blood</i> , 2001 , 97, 73-80	2.2	63
1271	Expression of the neuronal cyclin-dependent kinase 5 activator p35Nck5a in human monocytic cells is associated with differentiation. <i>Blood</i> , 2001 , 97, 3763-7	2.2	37
1270	Myeloblastin is an Myb target gene: mechanisms of regulation in myeloid leukemia cells growth-arrested by retinoic acid. <i>Blood</i> , 2001 , 97, 2449-56	2.2	37
1269	The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. <i>Blood</i> , 2001 , 98, 3290-300	2.2	49
1268	Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. <i>Blood</i> , 2001 , 98, 2651-6	2.2	80
1267	Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia. 2001 , 40, 1165		
1266	Exogenous PML/RAR-Fusion Gene Responds to All-trans Retinoic Acid Results in Differentiation of the Human B Cell Line. 2001 , 5, 455-62		
1265	Beneficial Effect of the Active Form of Vitamin D3 against LPS-induced DIC but not against Tissue-factor-induced DIC in Rat Models. 2001 , 85, 287-290		37
1264	Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. 2001 , 6, 11-16		2
1263	Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. 2001 , 80, 417-22		81
1262	The biology of acute promyelocytic leukemia. 2001 , 3, 209-16		13
1261	Effect of arsenic trioxide or ATRA on primary APL cell or HL-60 cells and their value analysis in hyperleukocytosis. 2001 , 13, 119-123		
1260	Molecular genetics in acute and chronic leukemias. 2001 , 127, 80-90		7
1259	Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres. 2001 , 215, 67-81		50
1258	Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. 2001 , 112, 315-26		55

1257	Induction of the monocytic differentiation of myeloid leukaemia cells by cotylenin A, a plant growth regulator. 2001 , 112, 697-705		23
1256	Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. 2001 , 113, 763-71		148
1255	Differentiation of human acute myeloid leukaemia cells in primary culture in response to cotylenin A, a plant growth regulator. 2001 , 114, 814-21		38
1254	Hypercalcemia due to all-trans retinoic acid therapy for acute promyelocytic leukemia: a case report of effective treatment with bisphosphonate. 2001 , 43, 688-90		17
1253	Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. 2001 , 16, 1329-35		32
1252	Antibody therapy for residual disease in acute myelogenous leukemia. 2001 , 38, 37-45		34
1251	International note: the walls of a spacious room. 2001 , 36, 312-3		2
1250	Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. 2001 , 15, 133-42		23
1249	The role of bone marrow transplantation in acute promyelocytic leukemia. 2001 , 28, 219-26		32
1248	Transcription factors and translocations in lymphoid and myeloid leukemia. 2001 , 15, 313-31		42
1247	A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. 2001 , 15, 1176-84		38
1246	Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. 2001 , 15, 1359-68		63
1245	Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13). <i>Oncogene</i> , 2001 , 20, 375-84	9.2	14
1244	Common themes in the pathogenesis of acute myeloid leukemia. <i>Oncogene</i> , 2001 , 20, 5680-94	9.2	60
1243	Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. <i>Oncogene</i> , 2001 , 20, 7161-77	9.2	31
1242	All trans retinoic acid in acute promyelocytic leukemia. <i>Oncogene</i> , 2001 , 20, 7140-5	9.2	165
1241	PML protein isoforms and the RBCC/TRIM motif. <i>Oncogene</i> , 2001 , 20, 7223-33	9.2	370
1240	APL, a model disease for cancer therapies?. <i>Oncogene</i> , 2001 , 20, 7136-9	9.2	19

1239	Transcriptional regulation in acute promyelocytic leukemia. <i>Oncogene</i> , 2001 , 20, 7204-15	9.2	141
1238	New-age drug meets resistance. 2001 , 412, 281-2		54
1237	Chromosome translocations: dangerous liaisons revisited. 2001 , 1, 245-50		220
1236	Effects of Matrine on proliferation and differentiation in K-562 cells. 2001 , 25, 793-800		82
1235	Retinoic acid-induced blr1 expression requires RARalpha, RXR, and MAPK activation and uses ERK2 but not JNK/SAPK to accelerate cell differentiation. 2001 , 80, 59-67		36
1234	Induction of differentiation of human myeloid leukemia cells by novel synthetic neurotrophic pyrimidine derivatives. 2001 , 29, 194-201		3
1233	Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. 2001 , 29, 864-72		34
1232	Apoptosis induction by acyclic retinoid: a molecular basis of 'clonal deletion' therapy for hepatocellular carcinoma. 2001 , 31, 359-62		8
1231	Acute Leukemias VIII. 2001 ,		1
1230	Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. 2001 , 6 Suppl 2, 11-6		56
1229	Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom. 2001 , 42, 665-74		28
1228	All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance. 2001 , 42, 739-46		8
1227	Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. 2001 , 42, 1265-73		15
1226	PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells. 2001 , 276, 22375-81		38
1225	Familiar drugs may prevent cancer. 2001 , 77, 492-7		3
1224	Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. 2001 , 93, 1224-33		89
1223	Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. 2001 , 21, 1747-58		117
1222	Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. 2001 , 276, 4012-9		136

1221	[Current therapeutic concept of acute promyelocytic leukemia]. 2001 , 126, 1073-9	1
1220	Acyclic carotenoids and their oxidation mixtures inhibit the growth of HL-60 human promyelocytic leukemia cells. 2001 , 39, 273-83	90
1219	Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. 2001 , 42, 309-16	16
1218	Cotylenin A—a plant growth regulator as a differentiation-inducing agent against myeloid leukemia. 2002 , 43, 1169-78	40
1217	New therapies in leukemia: renewed hope. 2002 , 11, 583-7	
1216	Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. 2002 , 16, 733-5	17
1215	Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. 2002 , 99, 7640-5	32
1214	Advances in the treatment of relapsed acute promyelocytic leukemia. 2002 , 107, 1-17	28
1213	A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RAR α mRNA. 2002 , 20, 127	2
1212	Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells. 2002 , 21, 127	2
1211	The anti-estrogenic effect of all-trans-retinoic acid on the breast cancer cell line MCF-7 is dependent on HES-1 expression. 2002 , 277, 28376-9	37
1210	Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers. 2002 , 277, 31491-8	120
1209	Derivatives of vitamins D2 and D3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. 2002 , 1, 410-5	52
1208	Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. 2002 , 2, 261-9	43
1207	The emergence of resistance to targeted cancer therapeutics. 2002 , 3, 603-23	21
1206	Classical and novel retinoids: their targets in cancer therapy. 2002 , 16, 463-72	121
1205	All-trans retinoic acid down-regulates prion protein expression independently of granulocyte maturation. 2002 , 16, 940-8	19
1204	A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation. 2002 , 16, 826-32	25

1203	Stimulation of vascular endothelial growth factor gene transcription by all trans retinoic acid through Sp1 and Sp3 sites in human bronchioloalveolar carcinoma cells. 2002 , 26, 246-53		46
1202	Radiologic features of all-trans-retinoic acid syndrome. 2002 , 178, 475-80		35
1201	Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. 2002 , 16, 617-22		81
1200	ASB-2 inhibits growth and promotes commitment in myeloid leukemia cells. 2002 , 277, 218-24		60
1199	Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol. 2002 , 16, 961-76		29
1198	Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. 2002 , 7 Suppl 1, 1-13		23
1197	Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines. 2002 , 64, 169-72		8
1196	The prospects of retinoids in the treatment of prostate cancer. 2002 , 13, 781-90		28
1195	The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. 2002 , 25, 49-56		15
1194	Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. 2002 , 24, 1-7		57
1193	Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. <i>Blood</i> , 2002 , 100, 594-602	2.2	173
1192	Acute promyelocytic leukemia: evolving therapeutic strategies. <i>Blood</i> , 2002 , 99, 759-67	2.2	331
1191	Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. <i>Blood</i> , 2002 , 99, 2985-91	2.2	78
1190	Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. <i>Blood</i> , 2002 , 99, 3136-43	2.2	180
1189	[Induction of cell differentiation and development of new anticancer drugs]. 2002 , 122, 547-63		4
1188	Ectopic expression of CXCR5/BLR1 accelerates retinoic acid- and vitamin D(3)-induced monocytic differentiation of U937 cells. 2002 , 227, 753-62		5
1187	High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-"pan" RAE-1 antibody confer tumor susceptibility to NK cells. 2002 , 290, 140-5		21
1186	Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. <i>Blood</i> , 2002 , 100, 1008-13	2.2	31

1185	Acute myeloid leukaemia: optimising treatment in elderly patients. 2002 , 19, 571-81		11
1184	Effects of bitter melon (<i>Momordica charantia</i> L.) or ginger rhizome (<i>Zingiber officinale</i> rosc) on spontaneous mammary tumorigenesis in SHN mice. 2002 , 30, 195-205		66
1183	Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones. 2002 , 43, 1729-35		16
1182	Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. 2002 , 36, 660-71		49
1181	FLT3 in human hematologic malignancies. 2002 , 43, 1541-7		59
1180	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. <i>Blood</i> , 2002 , 99, 1014-1022	2.2	82
1179	Retinoic acid receptors and cancer. 2002 , 132, 3809S-3813S		22
1178	Retinoids in liver fibrosis and cancer. 2002 , 7, d204-18		28
1177	RARA fluorescence in situ hybridization overcomes the drawback of PML/RARA fluorescence in situ hybridization in follow-up of acute promyelocytic leukemia. 2002 , 139, 104-8		4
1176	The emerging roles of translation factor eIF4E in the nucleus. 2002 , 70, 10-22		104
1175	Advances in the understanding and management of acute promyelocytic leukemia. 2002 , 6, 60-71; discussion 86-7		12
1174	The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. 2002 , 30, 1273-82		9
1173	Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. 2002 , 35, 261-70		14
1172	Resveratrol, a natural product derived from grapes, is a new inducer of differentiation in human myeloid leukemias. 2002 , 75, 528-33		36
1171	New advances in the treatment of acute promyelocytic leukemia. 2002 , 76 Suppl 2, 179-87		27
1170	Management of acute promyelocytic leukemia. 2002 , 4, 381-9		16
1169	Detection and its clinical value of minimal residual diseases in acute promyelocytic leukemia. 2002 , 14, 288-292		
1168	Synthesis and biological activity of retinoic acid receptor-alpha specific amides. 2002 , 12, 3145-8		32

1167	Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. 2002 , 12, 399-402		73
1166	All-trans retinoic acid prevents apoptosis of human marrow CD34+ cells deprived of haematopoietic growth factors. 2002 , 118, 289-95		8
1165	Superior effect of 9-cis retinoic acid (RA) compared with all-trans RA and 13-cis RA on the inhibition of clonogenic cell growth and the induction of apoptosis in OCI/AML-2 subclones: is the p53 pathway involved?. 2002 , 118, 401-10		5
1164	Nebulization of niosomal all-trans-retinoic acid: an inexpensive alternative to conventional liposomes. 2002 , 241, 311-7		41
1163	A metal chelator, diphenylthiocarbazone, induces apoptosis in acute promyelocytic leukemia (APL) cells mediated by a caspase-dependent pathway without a modulation of retinoic acid signaling pathways. 2002 , 26, 661-8		4
1162	Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid. 2002 , 26, 1097-103		10
1161	Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. 2002 , 16, 2275-84		63
1160	The role of retinoids and retinoic acid receptors in normal hematopoiesis. 2002 , 16, 1896-905		132
1159	Retinoic acid resistance in acute promyelocytic leukemia. 2002 , 16, 1940-58		117
1158	Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. 2002 , 16, 1906-17		31
1157	Signaling revisited in acute promyelocytic leukemia. 2002 , 16, 1933-9		11
1156	Transcription factor fusions in acute leukemia: variations on a theme. <i>Oncogene</i> , 2002 , 21, 3422-44	9.2	90
1155	Differentiation induction as a treatment for hematologic malignancies. <i>Oncogene</i> , 2002 , 21, 3496-506	9.2	25
1154	Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. 2002 , 112, 645-50		9
1153	How acute promyelocytic leukaemia revived arsenic. 2002 , 2, 705-13		272
1152	Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma. 2002 , 26, 745-55		12
1151	Structural genomics efforts at the Chinese Academy of Sciences and Peking University. 2003 , 4, 137-9		9
1150	Cytokine secretion in patients with acute promyelocytic leukemia after treatment with all-trans retinoic acid. 2003 , 15, 33-37		2

1149	Monitoring PML-RARalpha in acute promyelocytic leukemia. 2003 , 5, 391-8	5
1148	All- trans-retinoic acid increases cytotoxicity of 1-beta-D-arabinofuranosylcytosine in NB4 cells. 2003 , 51, 363-75	12
1147	Cancer in pregnancy: maternal-fetal conflict. 2003 , 129, 133-46	87
1146	The development of differentiation agents for the treatment of prostate cancer. 2003 , 30, 689-97	4
1145	Use of arsenic trioxide (As ₂ O ₃) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. 2003 , 97, 2218-24	106
1144	Ectopic p21 ^{sdi1} gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment. 2003 , 103, 833-9	24
1143	The synthetic retinoid RO 13-6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo. 2003 , 104, 418-24	16
1142	Adenine analogs as potential differentiation therapy agents for acute myeloid leukemia. 2003 , 59, 14-22	5
1141	Cell growth inhibition by all-trans retinoic acid in SKBR-3 breast cancer cells: involvement of protein kinase Calpha and extracellular signal-regulated kinase mitogen-activated protein kinase. 2003 , 38, 106-16	29
1140	Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. 2003 , 40, 293-301	20
1139	Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. 2003 , 27, 1019-25	30
1138	Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. 2003 , 259, 79-91	80
1137	The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. 2003 , 45, 129-50	60
1136	The history of acute promyelocytic leukaemia. 2003 , 122, 539-53	33
1135	Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. 2003 , 17, 1211-62	83
1134	Stem cells and diversity. 2003 , 17, 1042-8	12
1133	Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. 2003 , 17, 1333-7	64
1132	Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. 2003 , 17, 1454-63	130

1131	Retinoid target genes in acute promyelocytic leukemia. 2003 , 17, 1723-30		64
1130	The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. <i>Oncogene</i> , 2003 , 22, 4083-91	9.2	15
1129	Cancer revoked: oncogenes as therapeutic targets. 2003 , 3, 375-80		342
1128	Control of gut differentiation and intestinal-type gastric carcinogenesis. 2003 , 3, 592-600		266
1127	Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. 2003 , 170, 5793-8		72
1126	Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. 2003 , 17, 1405-19		30
1125	Intensified myeloablative therapy and autologous stem-cell transplantation for patients with AML: single center experience. 2003 , 5, 139-46		3
1124	Receptor induction and targeted drug delivery: a new antileukaemia strategy. 2003 , 3, 563-74		28
1123	Cross-talk between retinoic acid and STAT3 signaling pathways in acute promyelocytic leukemia. 2003 , 44, 2023-9		18
1122	Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. 2003 , 16, 433-51		24
1121	All-trans retinoic acid in acute promyelocytic leukaemia. 2003 , 16, 419-32		34
1120	Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management. 2003 , 7, 432-4		23
1119	Transcriptome study in China. 2003 , 326, 949-57		3
1118	Retinoids and retinoic acid receptor in cancer. 2003 , 1, 13-18		6
1117	3-Deazauridine triggers dose-dependent apoptosis in myeloid leukemia cells and enhances retinoic acid-induced granulocytic differentiation of HL-60 cells. 2003 , 35, 1482-94		8
1116	Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells. 2003 , 5, 212-21		31
1115	Acute promyelocytic leukaemia:a review. 2003 , 4, 1379-92		9
1114	Successful treatment for multiple cerebral hemorrhage in a newly diagnosed patient with acute promyelocytic leukemia. 2003 , 44, 1059-61		7

1113	Hematopoiesis and retinoids: development and disease. 2003 , 44, 1881-91	28
1112	Induction of differentiation in human promyelocytic leukemia HL-60 cell line by niacin-related compounds. 2003 , 67, 1132-5	24
1111	Fenretinide: a prototype cancer prevention drug. 2003 , 12, 1829-42	42
1110	Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. 2003 , 8, 132-40	46
1109	Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. 2003 , 21, 2326-34	128
1108	Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. 2003 , 21, 999-1006	89
1107	Activation of protein kinase C delta by all-trans-retinoic acid. 2003 , 278, 32544-51	94
1106	Effect of arsenic trioxide on QT interval in patients with advanced malignancies. 2003 , 21, 3609-15	184
1105	Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids. 2003 , 88, 1058-64	14
1104	The retinoic acid-responsive proline-rich protein is identified in promyeloleukemic HL-60 cells. 2003 , 278, 51685-92	9
1103	Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. 2003 , 278, 33422-35	80
1102	Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. 2003 , 1-13	39
1101	Pyranocoumarins isolated from <i>Peucedanum praeruptorum</i> as differentiation inducers in human leukemic HL-60 cells. 2003 , 69, 223-9	63
1100	Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation. 2003 , 44, 691-8	14
1099	Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?. 2003 , 3, 219-36	118
1098	Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. 2003 , 25, 594-600	18
1097	Vesnarinone: a differentiation-inducing anti-cancer drug. 2003 , 14, 391-5	6
1096	Investigation of the growth and metastasis of malignant melanoma in a murine model: the role of supplemental vitamin A. 2003 , 112, 152-8; discussion 159-61	15

1095	Effects on M5076-hepatic metastasis of retinoic acid and N-(4-hydroxyphenyl) retinamide, fenretinide entrapped in SG-liposomes. 2003 , 26, 1060-3		12
1094	CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. <i>Blood</i> , 2003 , 101, 1141-8	2.2	88
1093	JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. <i>Blood</i> , 2003 , 102, 3371-8	2.2	89
1092	Treatment of relapsed acute promyelocytic leukemia. 2003 , 26, 373-9		5
1091	Acute myeloid leukemia: a classification and treatment update. 2003 , 7, 535-40		8
1090	Retinoids: pleiotropic agents of therapy for vascular diseases?. 2003 , 3, 31-57		22
1089	Therapy of acute promyelocytic leukemia. 2004 , 51, 35-58		3
1088	Arsenates in the Treatment of Hematological Malignancies. 2004 , 02, 161-171		
1087	Retinoic acid receptor antagonist inhibits CD38 antigen expression on human hematopoietic cells in vitro. 2004 , 45, 1025-35		5
1086	Retinoids in cancer chemoprevention. 2004 , 4, 285-98		112
1085	Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid. 2004 , 45, 1017-24		10
1084	Retinoic acid syndrome after one dose of all-transretinoic acid. 2004 , 10, 149-154		5
1083	All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. 2004 , 101, 5328-35		485
1082	Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. 2004 , 64, 370-7		85
1081	Biography of Zhu Chen. 2004 , 101, 5325-7		
1080	Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. 2004 , 279, 18178-87		56
1079	A novel retinoic acid-responsive element regulates retinoic acid-induced BLR1 expression. 2004 , 24, 2423-43		37
1078	Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (Review). 2004 , 24, 797		2

1077	Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. 2004 , 182, 325-37	37
1076	Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. 2004 , 22, 1404-12	118
1075	Retinoic acid inhibits interleukin-4-induced eotaxin production in a human bronchial epithelial cell line. 2004 , 286, L777-85	18
1074	Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. 2004 , 5, 410-8	15
1073	Acute promyelocytic leukaemia presenting as postpartum haemorrhage. 2004 , 26, 233-7	10
1072	Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. 2004 , 2, 1341-50	117
1071	Gene expression as a drug discovery tool. 2004 , 36, 214-5	27
1070	Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. 2004 , 36, 257-63	240
1069	Nuclear structure in cancer cells. 2004 , 4, 677-87	703
1068	Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. 2004 , 18, 285-92	72
1067	Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. 2004 , 18, 1169-75	66
1066	Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. 2004 , 18, 1413-9	50
1065	Signaling pathways in retinoid chemoprevention and treatment of cancer. 2004 , 555, 81-96	88
1064	A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. 2004 , 94, 643-9	9
1063	Differential effects of 9-cis retinoic acid on expression of CC chemokine receptors in human monocytes. 2004 , 68, 611-20	13
1062	Apoptosis induced by molecular targeting therapy in hematological malignancies. 2004 , 111, 107-23	15
1061	Acute promyelocytic leukemia during pregnancy: report of 3 cases. 2004 , 79, 31-6	30
1060	All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia. 2004 , 83, 376-80	6

1059	Potential of the teratogenic effects induced by coadministration of retinoic acid or phytanic acid/phytol with synthetic retinoid receptor ligands. 2004 , 78, 660-8	16
1058	Identification of apoptotic tyrosine-phosphorylated proteins after etoposide or retinoic acid treatment. 2004 , 4, 1029-41	33
1057	All-trans-retinoic acid release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene glycol) diblock copolymer. 2004 , 273, 95-107	60
1056	Cytokines and retinoic acid therapy for APL: new tricks from an old combination. 2004 , 28, 447-8	0
1055	Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia. 2004 , 28, 1227-37	14
1054	Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature. 2004 , 28, 1347-50	12
1053	Arsenic trioxide in the treatment of haematological malignancies. 2004 , 3, 589-97	18
1052	A closer look at specific therapeutic strategies in leukemia. 2004 , 45, 1767-73	1
1051	The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. 2004 , 45, 639-48	31
1050	Antitumor activity of bruceantin: an old drug with new promise. 2004 , 67, 269-72	79
1049	[Applications of molecular biology to care of patients with malignant hematological disease]. 2004 , 62, 401-20	1
1048	Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. 2004 , 45, 2175-85	23
1047	Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation. 2004 , 206, 43-50	34
1046	Induction of cytochrome CYP4F3A in all-trans-retinoic acid-treated HL60 cells. 2004 , 314, 104-9	9
1045	Rab7b, a novel lysosome-associated small GTPase, is involved in monocytic differentiation of human acute promyelocytic leukemia cells. 2004 , 318, 792-9	54
1044	Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells. 2004 , 297, 68-81	62
1043	Retinoic acid receptors and cancers. 2004 , 24, 201-21	216
1042	Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. <i>Blood</i> , 2004 , 104, 3731-8	2.2 92

1041	Cytoplasm prepared from all-trans retinoic acid (ATRA)-treated human hematopoietic progenitor cells induces differentiation of both ATRA sensitive and ATRA resistant leukemia cells. 2004 , 27, 570-3		
1040	Implication of CDK inhibitors p21 and p27 in the differentiation of HL-60 cells. 2004 , 27, 992-7		9
1039	[Basic studies for the development of anticancer, antidementia, and taste modifier drugs]. 2004 , 124, 371-96		1
1038	Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. 2005 , 65, 7847-55		8
1037	Acute promyelocytic leukemia: a model of molecular target based therapy. 2005 , 10 Suppl 1, 270-80		15
1036	Arsenic in cancer therapy. 2005 , 16, 119-27		54
1035	Effects of retinoic acid steroidal analogs on human leukemic HL60 cell proliferation in vitro and on angiogenesis in vivo. 2005 , 16, 151-8		9
1034	Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. <i>Blood</i> , 2005 , 105, 1669-77	2.2	44
1033	Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment. 2005 , 44, 818-24		3
1032	Treatment concepts of acute promyelocytic leukemia. 2005 , 56, 261-74		70
1031	Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. 2005 , 82, 224-9		83
1030	Involvement of mitochondrial aggregation in arsenic trioxide (As ₂ O ₃)-induced apoptosis in human glioblastoma cells. 2005 , 96, 825-33		79
1029	Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. 2005 , 128, 853-62		32
1028	The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. 2005 , 139, 74-83		47
1027	A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia. 2005 , 27, 399-401		8
1026	WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential. 2005 , 19, 390-5		12
1025	High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. 2005 , 19, 978-83		40
1024	Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. 2005 , 19, 1812-7		28

1023	Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. <i>Oncogene</i> , 2005 , 24, 3358-68	9.2	43
1022	Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells. <i>Oncogene</i> , 2005 , 24, 4362-9	9.2	53
1021	Retinoid-induced activation of NF-kappaB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells. <i>Oncogene</i> , 2005 , 24, 7145-55	9.2	19
1020	Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis. 2005 , 33, 131-43		108
1019	Regulation of hematopoiesis by retinoid signaling. 2005 , 33, 1055-61		64
1018	Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. 2005 , 204, 964-74		61
1017	A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. 2005 , 114, 32-8		65
1016	Induction of murine leukemia and lymphoma by dominant negative retinoic acid receptor alpha. 2005 , 44, 252-61		6
1015	Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. 2005 , 94, 2606-15		31
1014	Mechanisms of the self/non-self-survey in the defense against cancer: potential for chemoprevention?. 2005 , 56, 5-22		8
1013	ISG15: a ubiquitin-like enigma. 2005 , 10, 2701-22		94
1012	Retinoic acid and arsenic for treating acute promyelocytic leukemia. 2005 , 2, e12		36
1011	ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex. 2005 , 280, 5468-74		59
1010	Formation of retinoylated proteins from retinoyl-CoA in rat tissues. 2005 , 138, 493-500		20
1009	Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. 2005 , 65, 7856-65		10
1008	Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. 2005 , 11, 71-6		61
1007	Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. 2005 , 67, 1808-17		57
1006	19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. 2005 , 65, 2488-97		33

1005	Biphenotypic acute leukemia with t(15;17). 2005 , 46, 607-10	9
1004	Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993). 2005 , 46, 377-85	7
1003	Molecular Pathogenesis of MDS. 2005 , 2005, 156-60	43
1002	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. 2005 , 102, 7653-8	208
1001	Tumoral drug metabolism: overview and its implications for cancer therapy. 2005 , 23, 205-29	123
1000	Mutant FLT3 signaling contributes to a block in myeloid differentiation. 2005 , 46, 1679-87	27
999	Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. 2005 , 11, 2702-12	84
998	Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. 2005 , 1, 239-250	
997	EGFR gene mutations: a call for global x global views of cancer. 2005 , 97, 326-8	23
996	Regulation of mast cell development. 2005 , 87, 1-21	22
995	Genital ulcers after treatment with all-trans-retinoic acid in a child with acute promyelocytic leukemia. 2005 , 22, 357-9	3
994	Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres. 2005 , 22, 877-89	27
993	Biological effects of ATRA and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts. 2005 , 46, 257-63	1
992	Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. 2005 , 332, 1140-5	10
991	Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha. 2005 , 219, 27-31	11
990	Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. 2005 , 116, 109-14	62
989	Vitamins A and E: metabolism, roles and transfer to offspring. 2005 , 93, 153-74	167
988	Synthetic retinoids: recent developments concerning structure and clinical utility. 2005 , 48, 5875-83	99

987	Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?. 2006 , 47, 2282-8	15
986	Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. 2006 , 47, 815-25	11
985	ThÉrapeutiques ciblÉes dans les leucÉmies aiguÉs. 2006 , 15, 278-284	1
984	Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. 2006 , 47, 1629-38	28
983	Evolving Role of Arsenic Trioxide in Acute Promyelocytic Leukemia. 2006 , 1, 36-40	1
982	Hematological disorders. 2006 , 3, 497-498	
981	Role of PML/RAR α in the pathogenesis of APL. 2006 , 3, 499-505	9
980	Microemulsion of Tween-80/n-Butylalcohol/H ₂ O System and Its Entrapment Efficiency of ATRA. 2006 , 27, 949-954	7
979	All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. 2006 , 174, 1352-60	71
978	Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis. 2006 , 119, 272-9	88
977	Chromatin structural elements and chromosomal translocations in leukemia. 2006 , 5, 1282-97	138
976	Differential regulation of CC chemokine receptors by 9-cis retinoic acid in the human mast cell line, HMC-1. 2006 , 79, 1293-300	10
975	Down-regulation of TRRAP-dependent hTERT and TRRAP-independent CAD activation by Myc/Max contributes to the differentiation of HL60 cells after exposure to DMSO. 2006 , 6, 1204-13	28
974	Differentiation Induction in Leukemia and Lymphoma. 2006 , 491-506	2
973	Historical perspective. 3-20	
972	Pregnane Glycosides. 2006 , 1, 1934578X0600100	8
971	Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. <i>Blood</i> , 2006 , 108, 2045-54	2.2 59
970	Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. <i>Blood</i> , 2006 , 107, 698-707	2.2 43

969	CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities. <i>Blood</i> , 2006 , 108, 2416-9	2.2	18
968	Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. 2006 , 6, 6095-106		71
967	Peroxisome proliferator-activated receptor gamma ligands stimulate myeloid differentiation and lipogenesis in human leukemia NB4 cells. 2006 , 48, 177-88		18
966	Guidelines on the management of acute myeloid leukaemia in adults. 2006 , 135, 450-74		109
965	Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. 2006 , 94, 513-23		26
964	Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. 2006 , 20, 599-603		14
963	DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. 2006 , 20, 800-6		42
962	Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. 2006 , 20, 1009-16		39
961	Molecular response in acute promyelocytic leukemia: a direct comparison of regular and real-time RT-PCR. 2006 , 20, 1393-9		9
960	The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. 2006 , 30, 60-8		29
959	The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML. 2006 , 30, 979-86		8
958	New therapeutic approach for myeloid leukemia: induction of apoptosis via modulation of reactive oxygen species production by natural compounds. 2006 , 83, 283-8		5
957	Global gene expression profiles associated with retinoic acid-induced differentiation of embryonal carcinoma cells. 2006 , 73, 796-824		28
956	All-trans retinoic acid-associated low molecular weight water-soluble chitosan nanoparticles based on ion complex. 2006 , 14, 66-72		26
955	Is cytarabine required in the treatment of acute promyelocytic leukemia?. 2006 , 1, 122-5		0
954	Chromatin control and cancer-drug discovery: realizing the promise. 2006 , 11, 97-109		65
953	Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. 2006 , 110, 514-21		44
952	Neoplastic stem cells: a novel therapeutic target in clinical oncology. 2006 , 107, 2512-20		65

951	Polyion complex micelles composed of all-trans retinoic acid and poly (ethylene glycol)-grafted-chitosan. 2006 , 95, 2348-60	62
950	Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. 2006 , 24, 5703-10	142
949	Differentiation-inducing therapy for solid tumors. 2006 , 12, 379-85	56
948	Granulocyte macrophage colony-stimulating factor enhances retinoic acid-induced gene expression. 2006 , 80, 889-96	4
947	Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). 2006 , 7, 159-70	6
946	Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. 2006 , 17, 131-4	155
945	Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. 2006 , 66, 5875-82	39
944	Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. 2006 , 47, 1062-8	47
943	Treatment of acute promyelocytic leukemia. 2006 , 2006, 147-55	52
942	RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. 2006 , 203, 1283-93	158
941	Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant cancer cells. 2007 , 67, 1019-29	18
940	Nuclear Hormone Receptors. 2007 , 993-1036	
939	Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. 2007 , 13, 1375-400	59
938	Forced expression of RDH10 gene retards growth of HepG2 cells. 2007 , 6, 238-44	12
937	Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. 2007 , 75, 301-54	20
936	NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. 2007 , 26, 269-81	18
935	Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. 2007 , 362, 959-71	106
934	Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. 2007 , 104, 13438-43	56

933	Treatment of acute promyelocytic leukemia by retinoids. 2007 , 313, 101-28		50
932	Current status and future of target-based therapeutics. 2007 , 7, 273-84		6
931	Recent developments in acute myelogenous leukemia therapy. 2007 , 12 Suppl 2, 14-21		17
930	2. All-trans retinoic acid in the treatment of acute promyelocytic leukemia. 2007 , 46, 91-3		17
929	Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. <i>Blood</i> , 2007 , 109, 3441-50	2.2	161
928	Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors. <i>Blood</i> , 2007 , 109, 971-9	2.2	46
927	A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. <i>Blood</i> , 2007 , 110, 59-66	2.2	134
926	Oncogenic signaling in acute myeloid leukemia. 2007 , 8, 237-46		9
925	A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. 2007 , 28, 251-5		38
924	Role of interleukin-8 and growth-regulated oncogene-alpha in the chemotactic migration of all-trans retinoic acid-treated promyelocytic leukemic cells toward alveolar epithelial cells. 2007 , 35, 879-85		29
923	Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. 2007 , 83, 375-84		20
922	Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. 2007 , 13, 997-1004		12
921	Arsenical-based cancer drugs. 2007 , 33, 542-64		299
920	Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells. 2008 , 104, 89-99		6
919	Acute Promyelocytic Leukemia. 2007 ,		1
918	The Management of Acute Promyelocytic Leukemia Presenting During Pregnancy. 2007 , 1, 183-191		14
917	Acute Myelogenous Leukemia. 2007 ,		
916	Agents under investigation for the treatment and prevention of neutropenia. 2007 , 16, 1831-40		6

915	Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. 2007 , 6, 3808-18		33
914	Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. 2007 , 98, 191-220		5
913	Selection of keynote addresses presented at the Acute Leukemia Forum 2006. March 31, 2006. San Francisco, California, USA. 2007 , 20, 1-118		1
912	RAR β s a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. 2007 ,		
911	Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling. 2007 , 2, 117727190700200		5
910	Inhibitory effects of retinoic acid receptor alpha stimulants on murine cataractogenesis through suppression of deregulated calpains. 2007 , 48, 2224-9		9
909	All-trans retinoic acid release from polyion-complex micelles of methoxy poly(ethylene glycol) grafted chitosan. 2007 , 105, 3246-3254		28
908	Retinoic Acid and Arsenic Trioxide Treatment in Acute Promyelocytic Leukemia: A Model of Oncoprotein Targeted Therapy. 371-392		
907	Retinoids in biological control and cancer. 2007 , 102, 886-98		92
906	Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. 2007 , 109, 1355-9		72
905	Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon-gamma/interleukin-1beta-dependent apoptosis of endothelial cells: implications in the etiology of retinoic acid syndrome. 2007 , 31, 455-63		24
904	KN-62 analogues as potent differentiating agents of HL-60 cells. 2007 , 31, 683-9		3
903	Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. <i>Oncogene</i> , 2007 , 26, 91-101	9.2	59
902	HDAC3: taking the SMRT-N-CoRrect road to repression. <i>Oncogene</i> , 2007 , 26, 5439-49	9.2	171
901	Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. 2007 , 17, 274-6		43
900	Diverse actions of retinoid receptors in cancer prevention and treatment. 2007 , 75, 853-70		140
899	Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents. 2007 , 98, 1643-51		13
898	Leukemia, an effective model for chemical biology and target therapy. 2007 , 28, 1316-24		11

897	From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. 2007 , 28, 1434-49	7
896	The bioactive lipid sphingosylphosphorylcholine induces differentiation of mouse embryonic stem cells and human promyelocytic leukaemia cells. 2007 , 19, 367-77	38
895	Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. 2007 , 17, 248-56	79
894	PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic trioxide) for acute promyelocytic leukemia. 2007 , 12, 313-7	40
893	Diagnosis and treatment of acute promyelocytic leukemia. 2007 , 9, 337-44	33
892	All-trans retinoic acid release from surfactant-free nanoparticles of poly(DL-lactide-co-glycolide). 2008 , 16, 717-724	10
891	Biological significance of myeloperoxidase (MPO) on green tea component, (–)-epigallocatechin-3-gallate (EGCG)-induced apoptosis: its therapeutic potential for myeloid leukemia. 2008 , 3, 45-50	3
890	Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. 2008 , 13, 915-28	8
889	Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase gamma. 2008 , 134, 861-72	9
888	Antitumor effect of all-trans retinoic acid-encapsulated nanoparticles of methoxy poly(ethylene glycol)-conjugated chitosan against CT-26 colon carcinoma in vitro. 2008 , 97, 4011-9	26
887	Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy. 2008 , 104, 2059-70	19
886	Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. 2008 , 48, 1528-39	151
885	Relationship between the induction of leukemia cell differentiation and the enhancement of reporter gene expression in 3T3 Swiss cells. 2008 , 32, 89-96	4
884	Multiple exploitable molecular targets for differentiation therapy of leukemias. 2008 , 32, 1-2	1
883	Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid. 2008 , 32, 297-307	17
882	Induction of differentiation of myeloid leukemia cells in primary culture in response to lithocholic acid acetate, a bile acid derivative, and cooperative effects with another differentiation inducer, cotylenin A. 2008 , 32, 1112-23	8
881	Synthesis of 1-substituted 3-pyridinylmethylidenedolindolin-2-ones and 1-substituted 3-quinolinylmethylidenedolindolin-2-ones as the enhancers of ATRA-induced differentiation in HL-60 cells. 2008 , 16, 4222-32	11
880	Synthesis and cellular effects of cycloterpenals: cyclohexadienal-based activators of neurite outgrowth. 2008 , 16, 7573-81	11

879	Nuclear microenvironment in cancer diagnosis and treatment. 2008 , 104, 1953-63	6
878	Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. 2008 , 154, 1196-205	12
877	Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds. 2008 , 155, 814-25	22
876	The history of myeloproliferative disorders: before and after Dameshek. 2008 , 22, 3-13	59
875	Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. 2008 , 99, 689-95	37
874	PML/RAR alpha fusion gene is expressed in both granuloid/macrophage and erythroid colonies in acute promyelocytic leukaemia. 1993 , 85, 477-82	15
873	Life-threatening hepatic toxicity caused by all-trans-retinoic acid in a patient with acute promyelocytic leukaemia. 1994 , 16, 191-5	3
872	Chromosome abnormalities, clinical features and molecular mechanism in leukemia. 1991 , 41, 713-21	
871	Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. 2008 , 1786, 87-104	52
870	Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation. 2008 , 591, 7-12	46
869	A comprehensive review of acute promyelocytic leukemia in children. 2008 , 119, 73-82	18
868	Acute promyelocytic leukemia: from highly fatal to highly curable. <i>Blood</i> , 2008 , 111, 2505-15	2.2 923
867	Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids. 2008 , 368, 983-9	8
866	Differential gene expression patterns coupled to commitment and acquisition of phenotypic hallmarks during neutrophil differentiation of human leukaemia HL-60 cells. 2008 , 419, 16-26	34
865	Arsenic trioxide. 2008 , 9, 1773-85	42
864	Proteins in human myeloid leukemia cell line HL60 reacting with retinoic acid monoclonal antibodies. 2008 , 144, 349-55	13
863	Curative strategies in acute promyelocytic leukemia. 2008 , 391-9	47
862	Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. 2008 , 105, 4826-31	57 ^o

861	Innovative Leukemia and Lymphoma Therapy. 2008 ,		
860	New therapeutic approaches to acute myeloid leukemia. 2008 , 3, 689-706		2
859	Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. <i>Blood</i> , 2008 , 112, 2305-17	2.2	78
858	Transcriptome and proteome analyses of drug interactions with natural products. 2008 , 9, 1038-48		16
857	Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital. 2008 , 30, 387-90		8
856	Effect of Indole-3-Acetic Acid Analogs on the Differentiation of HL-60 Cells. 2008 , 55, 1160-1165		1
855	. 2008 ,		3
854	Cancer Stem Cells. 2008 , 141-154		1
853	[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases]. 2008 , 24, 967-71		4
852	Nuclear Receptor Drug Discovery. 2008 , 275-316		
851	PML nuclear bodies and their spatial relationships in the mammalian cell nucleus. 2009 , 14, 1182-96		15
850	PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?. 2009 , 14, 1684-707		24
849	Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. 2009 , 106, 3342-7		314
848	A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation. 2009 , 8, 1719-27		39
847	Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. 2009 , 121, 1-8		43
846	Cell nanomechanics and focal adhesions are regulated by retinol and conjugated linoleic acid in a dose-dependent manner. 2009 , 20, 285103		11
845	Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. 2009 , 27, 2668-76		78
844	Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. 2009 , 27, 504-10		306

843	Differentiation therapy of acute myeloid leukemia: past, present and future. 2009 , 16, 84-91	136
842	Effect of retinoids on growth and differentiation of myeloid leukemia cells. 1989 , 47, 153-4	1
841	All-trans and 13-cis-retinoic acids are normal constituents of human blood formed from all-trans-retinyl palmitate. 1991 , 49, 283-4	
840	Vitamin A in epithelial differentiation and skin carcinogenesis. 1994 , 52, S45-52	30
839	Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation. 1991 , 46, 93-100	10
838	PML/RAR-alpha rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation. 1992 , 48, 173-6	34
837	Management of acute promyelocytic leukemia. 1993 , 50, 65-73	20
836	Advantage of induction therapy with all trans retinoic acid in acute promyelocytic leukaemia in a country with limited transfusion resources: a Malaysian experience. 1994 , 53, 237-41	2
835	Four-chromosomes complex translocations in acute promyelocytic leukemia: description of two cases. 1994 , 52, 129-33	14
834	Uptake and storage of retinol and retinyl esters in bone marrow of children with acute myeloid leukemia treated with high-dose retinyl palmitate. 1994 , 52, 140-4	8
833	Hypercalcaemia caused by all-trans retinoic acid treatment of acute promyelocytic leukaemia: case report. 1994 , 53, 126-7	15
832	All-trans retinoic acid and in vitro cytokine production by acute promyelocytic leukemia cells. 1996 , 57, 301-6	9
831	Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative Group. 1998 , 61, 327-32	18
830	All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. 1999 , 63, 149-53	12
829	In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells. 1999 , 63, 11-8	43
828	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. 2009 , 37, 1176-1185.e21	14
827	Profiling CD antigens on leukaemias with an antibody microarray. 2009 , 583, 1785-91	17
826	Linking somatic genetic alterations in cancer to therapeutics. 2009 , 21, 304-10	54

825	ICAT as a potential enhancer of monocytic differentiation: implications from the comparative proteome analysis of the HL60 cell line stimulated by all-trans retinoic acid and NSC67657. 2009 , 27, 329-37	2
824	Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. 2009 , 124, 827-33	41
823	Glycogen synthase kinases-3beta controls differentiation of malignant glioma cells. 2010 , 127, 1271-82	21
822	HPLC method for simultaneous determination of retinoids and tocopherols in human serum for monitoring of anticancer therapy. 2009 , 32, 2804-11	15
821	Tretinoin overdose: a first case report. 2009 , 5, 73-5	
820	Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells. 2009 , 54, 4094-4101	2
819	Granulocytic differentiation of HL-60 promyelocytic leukemia cells is associated with increased expression of Cul5. 2009 , 45, 264-74	12
818	New drugs in the treatment of acute myeloid leukaemia. 2009 , 2, 75-79	0
817	Isolated central nervous system recurrence of acute promyelocytic leukemia in children. 2009 , 52, 11-3	20
816	Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture. 2009 , 23, 753-60	20
815	Orphan nuclear receptor Nur77 is required for the differentiation of C6 glioma cells induced by cholera toxin. 2009 , 30, 1543-9	2
814	The molecular programme of tumour reversion: the steps beyond malignant transformation. 2009 , 9, 206-16	123
813	Triterpenoids isolated from the aerial parts of <i>Salvia chinensis</i> . 2009 , 2, 81-84	8
812	Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. 2009 , 33, 1072-8	7
811	Inhibition of all-trans retinoic acid-induced granulocytic differentiation of WEHI-3B D+ cells by forced expression of SCL (TAL1) and GATA-1. 2009 , 33, 1249-54	1
810	The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. 2009 , 277, 82-90	26
809	Telomerase regulation in hematological cancers: a matter of stemness?. 2009 , 1792, 229-39	19
808	Impact of drug discovery on stem cell biology. 2009 , 383, 275-9	7

807	Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. 2009 , 390, 60-4		9
806	Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation. 2009 , 16, 297-303		17
805	Next-generation sequencing of cancer genomes: back to the future. 2009 , 6, 653		20
804	Acute promyelocytic leukemia: a paradigm for differentiation therapy. 2010 , 145, 219-35		50
803	Growth and differentiation factors as cancer therapeutics. 2009 , 527-568		
802	HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance. 2009 , 28, 63		6
801	Bioinformatics in Cancer and Cancer Therapy. 2009 ,		1
800	Biology of Stem Cells and the Molecular Basis of the Stem State. 2009 ,		15
799	The role of CYP26 enzymes in retinoic acid clearance. 2009 , 5, 875-86		121
798	Demonstration of basic proteins that bind retinoic acid in the human myeloid leukemia cell line HL60. 2009 , 32, 1943-6		5
797	Differentiation therapy of leukemia: 3 decades of development. <i>Blood</i> , 2009 , 113, 3655-65	2.2	247
796	Disposition of a new tamibarotene prodrug in mice. 2009 , 32, 1997-2001		5
795	Tumor cell growth inhibition and cell differentiation analysis in a canine mammary tumor cell line (MCM-B2) treated with four chemical reagents. 2009 , 71, 1413-7		8
794	Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. <i>Blood</i> , 2010 , 116, 3933-43	2.2	27
793	Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. <i>Blood</i> , 2010 , 116, e26-34	2.2	66
792	Low Molecular Weight Water Soluble Chitosan with Free Amine Group for Drug Delivery. 2010 , 325-337		
791	Vitamin A in Health. 2010 , 56, 144-153		4
790	Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. <i>Blood</i> , 2010 , 116, 4938-47	2.2	38

789	Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. 2004 , 56, 1527-35	187
788	Molecular mechanisms of leukemia-associated protein degradation. 2010 , 4, 363-70	2
787	From carrot to clinic: an overview of the retinoic acid signaling pathway. 2010 , 67, 1423-45	228
786	Interactions of alpha1-proteinase inhibitor with small ligands of therapeutic potential: binding with retinoic acid. 2010 , 38, 1011-20	9
785	Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. 2010 , 91, 742-7	36
784	C/EBP β and CHOP participate in tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro. 2010 , 92, 571-8	17
783	Successful treatment with retinoids in patients with lupus nephritis. 2010 , 55, 344-7	34
782	New trends in encapsulation of liposoluble vitamins. 2010 , 146, 276-90	239
781	Induction of cell cycle arrest at G1 and S phases and cAMP-dependent differentiation in C6 glioma by low concentration of cycloheximide. <i>BMC Cancer</i> , 2010 , 10, 684	4.8 35
780	The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. 2010 , 80, 903-12	55
779	Application of Arsenic Trioxide Therapy for Patients with Leukaemia. 2010 , 263-292	6
778	NB4 cells treated with all-trans retinoic acid generate toxic reactive oxygen species that cause endothelial hyperpermeability. 2010 , 34, 373-8	8
777	Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy. 2010 , 34, 553-65	49
776	Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations. 2010 , 34, 649-57	28
775	ATRA is effective to an acute promyelocytic leukemia patient without RARA gene rearrangement. 2010 , 34, e190-3	5
774	Poly(lactic-co-glycolic acid) electrospun fibrous meshes for the controlled release of retinoic acid. 2010 , 6, 1258-68	86
773	The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. 2010 , 24, 1249-57	87
772	Response to letter by Pulsipher et al. 2010 , 24, 1532-3	1

771	Selective inhibition of BET bromodomains. 2010 , 468, 1067-73	2725
770	Leukaemogenesis: more than mutant genes. 2010 , 10, 23-36	243
769	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. 2010 , 10, 775-83	350
768	Clinical implications of the cancer genome. 2010 , 28, 5219-28	156
767	A case of ischemic stroke in acute promyelocytic leukemia at initial presentation. Relevance of all-trans retinoic acid treatment. 2010 , 10, 1-6	4
766	Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. 2010 , 9, 678-84	21
765	Acute Myelogenous Leukemia. 2010 ,	
764	Defined factors induce reprogramming of gastrointestinal cancer cells. 2010 , 107, 40-5	230
763	Glycogen synthase kinase-3beta regulates astrocytic differentiation of U87-MG human glioblastoma cells. 2010 , 31, 355-60	8
762	Minireview: Nuclear receptors, hematopoiesis, and stem cells. 2010 , 24, 1-10	29
761	Liposomal formulation of retinoids designed for enzyme triggered release. 2010 , 53, 3782-92	67
760	Acute Myeloid Leukemia. 2010 , 45-139	1
759	Classification and risk stratification for acute promyelocytic leukemia. 2010 , 10 Suppl 3, S127-9	0
758	Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. 2010 , 328, 240-3	563
757	Molecular networks for the study of TCM pharmacology. 2010 , 11, 417-30	164
756	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. 2010 , 295, 229-35	9
755	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. 2010 , 298, 9-15	38
754	The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells. 2010 , 393, 6-10	9

753	Molecularly Targeted Therapy for Childhood Cancer. 2010 ,	1
752	Acute promyelocytic leukemia: what are the treatment options?. 2010 , 11, 587-96	15
751	Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. 2010 , 51, 1734-47	37
750	Mylabris Phalerata (Chinese Blister Beetle) on Hematological Malignancies. 2011 , 375-388	2
749	The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells. 2011 , 11, 317-29	48
748	Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells. 2011 , 5, 265-72	24
747	All trans retinoic acid and cancer. 2011 , 33, 241-9	133
746	Curing all patients with acute promyelocytic leukemia: are we there yet?. 2011 , 25, 1215-33, viii	14
745	Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. 2011 , 29, 2753-7	176
744	Cancer Systems Biology, Bioinformatics and Medicine. 2011 ,	3
743	A blueprint for advancing genetics-based cancer therapy. 2011 , 147, 26-31	58
742	Inhibition of PCGF2 enhances granulocytic differentiation of acute promyelocytic leukemia cell line HL-60 via induction of HOXA7. 2011 , 416, 86-91	16
741	Manifestaci3n de leucemia promieloc3tica aguda en el embarazo. 2011 , 54, 428-430	1
740	The Molecular Mechanism for Differentiation Therapy of Malignant Glioma. 2011 ,	
739	Acute Promyelocytic Leukaemia: An Experience with 6 Cases. 2011 , 12, 139-141	1
738	Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. 2011 , 6, e16382	29
737	Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. 2011 , 6, e21419	87
736	From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. <i>Blood</i> , 2011 , 117, 6425-37	2.2 138

735	Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. <i>Blood</i> , 2011 , 118, 1600-9	2.2	84
734	Revisiting the differentiation paradigm in acute promyelocytic leukemia. <i>Blood</i> , 2011 , 117, 5795-802	2.2	103
733	Effects of novel all-trans retinoic acid retinamide derivatives on the proliferation and apoptosis of human lung adenocarcinoma cell line A549 cells. 2011 , 131, 1465-72		4
732	[Biological functions of the duplicated GGAA-motifs in various human promoter regions]. 2011 , 131, 1787-800		1
731	Acute myeloid leukemia. 2011 , 9, 280-317		45
730	Advances in therapies for acute promyelocytic leukemia. 2011 , 102, 1929-37		37
729	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. 2011 , 17, 304-12		77
728	Towards novel paradigms for cancer therapy. <i>Oncogene</i> , 2011 , 30, 1-20	9.2	93
727	LIF in the regulation of T-cell fate and as a potential therapeutic. 2011 , 12, 157-68		67
726	The screening toolbox of bioactive substances from natural products: a review. 2011 , 82, 1141-51		49
725	Current treatment strategy of acute promyelocytic leukemia. 2011 , 5, 341-7		17
724	ACUTE LEUKEMIAS XIII. 2011 , 90, 25-76		
723	Anti-cancer effects of 20(S)-protopanaxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4;11. 2011 , 28, 813-21		14
722	Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma. 2011 , 34, 407-17		32
721	Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction. 2011 , 5, 45-52		3
720	Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice. 2011 , 54, 2036-47		61
719	Therapeutic effect of retinoic acid on unilateral ureteral obstruction model. 2011 , 118, e69-78		22
718	Azadirachtin interacts with retinoic acid receptors and inhibits retinoic acid-mediated biological responses. 2011 , 286, 4690-702		17

717	Study on cytochrome p-450 dependent retinoic Acid metabolism and its inhibitors as potential agents for cancer therapy. 2011 , 79, 921-35	9
716	Emerging new approaches for the treatment of acute promyelocytic leukemia. 2011 , 2, 335-52	12
715	Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?. 2011 , 4, 427-36	8
714	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. 2011 , 10, 1378-84	367
713	Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. 2011 , 48, 316-22	12
712	Effects of PPAR γ Ligands on Leukemia. 2012 , 2012, 483656	13
711	Late Relapse of Acute Promyelocytic Leukemia: Literature Review and Results of Seven Years of Clinical and Laboratory Follow-Up of a Korean Patient. 2012 , 43, 205-211	
710	Retinoic acid attenuates rheumatoid inflammation in mice. 2012 , 189, 1062-71	79
709	Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1 α ,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance. 2012 , 11, 1364-73	8
708	Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. 2012 , 26, 433-42	121
707	MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. 2012 , 81, 292-8	45
706	Pathogenesis and treatment of leukemia: an Asian perspective. 2012 , 16 Suppl 1, S37-43	4
705	Advanced prostate cancer--a case for adjuvant differentiation therapy. 2012 , 9, 595-602	27
704	Reply to M. Keyhani and N. Mahmoudi. 2012 , 30, 220-222	1
703	Prise en charge thérapeutique des leucémies aiguës myéloblastes. 2012 , 7, 1-17	
702	Angiogenesis in Hepatocellular Carcinoma: A Potential Target for Chemoprevention and Therapy. 2012 , 12, 1095-1118	1
701	New Therapeutic Approach of Retinoids for Lupus Nephritis. 2012 , 03,	
700	Molecular genetics of acute myeloid leukemia. 204-238	1

699	[109th Scientific Meeting of the Japanese Society of Internal Medicine: invited lecture: 5. Molecular target therapy for leukemia]. 2012 , 101, 2497-504		
698	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i> , 2012 , 120, 1570-80; quiz 1752	2.2	213
697	A Meg by any other name. <i>Blood</i> , 2012 , 120, 1970-1	2.2	
696	Mutation associations in RA-defiant APL. <i>Blood</i> , 2012 , 120, 1969-70	2.2	
695	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. 2012 , 35, 1206-12		62
694	Formulation study on retinoic acid gel composed of iota-carrageenan, polyethylene oxide and Emulgen [®] 408. 2012 , 60, 825-30		6
693	From oncogene to tumor suppressor: the dual role of Myc in leukemia. 2012 , 11, 1757-64		35
692	Reversal by RAR β agonist Am580 of c-Myc-induced imbalance in RAR α /RAR β expression during MMTV-Myc tumorigenesis. 2012 , 14, R121		29
691	Recent advances in cancer stem cell research for cholangiocarcinoma. 2012 , 19, 606-13		35
690	Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation. 2012 , 132, 220-6		29
689	Mechanisms and impacts of chromosomal translocations in cancers. 2012 , 6, 263-74		15
688	TRIM32 promotes retinoic acid receptor β -mediated differentiation in human promyelogenous leukemic cell line HL60. 2012 , 417, 594-600		13
687	Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma. 2012 , 420, 516-22		
686	The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. 2012 , 41, 13239-57		90
685	Case of pediatric acute promyelocytic leukemia presenting as extramedullary tumor of the mandible. 2013 , 35, E310-3		11
684	All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. 2012 , 12, 1191-204		33
683	Role of randomized phase III trials in an era of effective targeted therapies. 2011 , 9, 208-14		39
682	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. 2012 , 483, 613-7		361

681	Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy. 2012 , 20, 6877-84	10
680	Discovery of small molecule cancer drugs: successes, challenges and opportunities. 2012 , 6, 155-76	363
679	Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. 2012 , 12, 1289-97	4
678	Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma. 2012 , 29, 747-62	47
677	Conformational Analysis of Free and Bound Retinoic Acid. 2012 , 8, 1436-1448	17
676	Intermittent Hypoxia and Human Diseases. 2012 ,	11
675	[Therapeutic effect of retinoic acid in lupus nephritis]. 2012 , 35, 1-7	9
674	Activating Mutations and Targeted Therapy in Cancer. 2012 ,	3
673	Combinatorial drug therapy for cancer in the post-genomic era. 2012 , 30, 679-92	670
672	Annexin A1 mediates the anti-inflammatory effects during the granulocytic differentiation process in all-trans retinoic acid-treated acute promyelocytic leukemic cells. 2012 , 227, 3661-9	12
671	Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. 2012 , 64, 671-5	8
670	How to manage acute promyelocytic leukemia. 2012 , 26, 1743-51	70
669	Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. 2012 , 118, 5811-8	53
668	Biofunctional nanoparticle formation and folate-targeted antitumor effect of heparin-retinoic acid conjugates. 2012 , 20, 520-527	3
667	Cancer stem cells: an evolving concept. 2012 , 12, 133-43	877
666	Arsenic compounds: revived ancient remedies in the fight against human malignancies. 2012 , 16, 92-8	56
665	Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells. 2012 , 422, 454-61	27
664	Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype. 2012 , 8, 330-6	4

663	Role of lipoxin A4 in the cell-to-cell interaction between all-trans retinoic acid-treated acute promyelocytic leukemic cells and alveolar macrophages. 2012 , 227, 1123-9	7
662	Stochastic gene expression stabilization as a new therapeutic strategy for cancer. 2012 , 34, 170-3	17
661	Search for chromosome rearrangements: new approaches toward discovery of novel translocations in head and neck squamous cell carcinoma. 2013 , 35, 831-5	1
660	Stem Cells and Prostate Cancer. 2013 ,	1
659	Role of arsenic trioxide in acute promyelocytic leukemia. 2013 , 14, 170-84	34
658	Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). 2013 , 97, 388-96	4
657	A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. 2013 , 56, 495-502	33
656	Importance of ERK activation in As ₂ O ₃ -induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells. 2013 , 77, 11-21	5
655	Independent research of China in Science Citation Index Expanded during 1980-2011. 2013 , 7, 210-222	40
654	Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. 2013 , 341, 16-23	23
653	Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. 2013 , 41, 125-38	65
652	BreakTrans: uncovering the genomic architecture of gene fusions. 2013 , 14, R87	18
651	Bone morphogenetic proteins regulate differentiation of human promyelocytic leukemia cells. 2013 , 37, 705-12	8
650	A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?. 2013 , 91, 470-1	17
649	Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. 2013 , 13, 1035-43	10
648	A new chromosome translocation t(7;16)(q31,q22) change during an acute promyelocytic leukemia relapse. 2013 , 141, 70-4	
647	Targeting peroxiredoxins against leukemia. 2013 , 319, 170-6	24
646	Clinical Genome Sequencing. 2013 , 102-122	24

645	Structural changes of β -carotene and some retinoid pharmaceuticals induced by environmental factors. 2013 , 1037, 99-108	9
644	Leukemias. 2013 , 675-690	
643	Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin. 2013 , 270, 695-704	3
642	All-trans retinoic acid displays multiple effects on the growth, lipogenesis and adipokine gene expression of AML-1 preadipocyte cell line. 2013 , 37, 36-46	13
641	Annexin A1 mediates the anti-adhesive effects of the dexamethasone-treated promyelocytic leukemic cells. 2013 , 114, 551-7	4
640	All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129. 2013 , 37, 795-801	31
639	"It's effective therapy, stupid!". 2013 , 37, 1434-5	1
638	How animal models of leukaemias have already benefited patients. 2013 , 7, 224-31	5
637	Leczenie celowane w ostrych białczkach szpikowych. 2013 , 44, 85-92	
636	Korean red ginseng extract induces proliferation to differentiation transition of human acute promyelocytic leukemia cells via MYC-SKP2-CDKN1B axis. 2013 , 150, 700-7	8
635	A novel acidic serine protease, ASPNJ inhibits proliferation, induces apoptosis and enhances chemo-susceptibility of acute promyelocytic leukemia cell. 2013 , 37, 1697-703	4
634	Using functional genomics to overcome therapeutic resistance in hematological malignancies. 2013 , 55, 100-15	7
633	Acute Promyelocytic Leukemia. 2013 , 403-453	
632	Therapy-Related Acute Myelogenous Leukemia. 2013 , 455-486	1
631	ATRA and the specific RAR α agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. 2013 , 27, 1369-80	16
630	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As ₂ O ₃) in acute promyelocytic leukemia. 2013 , 97, 717-25	126
629	Drugs as matrix to detect their own drug delivery system of PEG-b-PCL block copolymers in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 2013 , 27, 2201-12	4
628	All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. 2013 , 59, 1255-63	69

627	Development of a curative treatment within the AML-BFM studies. 2013 , 225 Suppl 1, S79-86		15
626	CEBPA-CEBPG axis as a novel promising therapeutic target in acute myeloid leukemia. 2013 , 34, 185-6		1
625	Differential Roles of PML Isoforms. <i>Frontiers in Oncology</i> , 2013 , 3, 125	5:3	101
624	Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. 2013 , 31, 370-9		61
623	New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers. <i>Frontiers in Oncology</i> , 2013 , 3, 124	5:3	12
622	Synergy against PML-RARα: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. 2013 , 210, 2793-802		93
621	Retinoid Signaling in Cancer and Its Promise for Therapy. 2013 ,		7
620	Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. 2013 , 210, 647-53		63
619	Update on optimal management of acute myeloid leukemia. 2013 , 7, 181-97		10
618	Developmental disease and cancer: biological and clinical overlaps. 2013 , 161A, 2788-96		23
617	All-Trans Retinoic Acid-Induced Myositis and Retinoic Acid Syndrome in Microgranular-Variant Acute Promyelocytic Leukemia. 2013 , 44, 348-352		1
616	PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17). 2013 , 19, 2562-71		29
615	Impact of chromosomal translocation and genomic instability on personalized medicine. 2013 , 10, 111-114		
614	Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias. 2013 , 21, 23-31		7
613	All-trans retinoic acid-incorporated nanoparticles of deoxycholic acid-conjugated dextran for treatment of CT26 colorectal carcinoma cells. 2013 , 8, 485-93		10
612	Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. 2013 , 32, 594-603		68
611	Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea. 2013 , 48, 31-4		1
610	ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. 2014 , 9, e104610		11

609	Signaling by Retinoic Acid in Embryonic and Adult Hematopoiesis. 2014 , 2, 18-33		3
608	Treatment of Acute Myeloid Leukemia. 2014 , 02,		2
607	The leukemias: a half-century of discovery. 2014 , 32, 3463-9		43
606	MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagy-lysosomal pathway in acute promyelocytic leukemia. 2014 , 10, 1726-37		39
605	Translational hematology. 2014 , 164, 487-96		
604	Open-access synthetic spike-in mRNA-seq data for cancer gene fusions. 2014 , 15, 824		19
603	Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RAR α promoter region. 2014 , 4, e205		25
602	all-trans-retinoic acid improves immunocompetence in a murine model of lipopolysaccharide-induced immunosuppression. 2014 , 126, 355-65		13
601	Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogs. <i>Frontiers in Oncology</i> , 2014 , 4, 125	5.3	29
600	References. 2014 , 179-224		
599	Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. 2014 , 7, 439-64		16
598	Acute promyelocytic leukemia: what is the new standard of care?. 2014 , 28, 205-12		55
597	Correction of all-trans retinoic acid deficiency in alcoholic cirrhosis lessens the excessive inflammatory monocyte response: a translational study. 2014 , 34, 343-52		8
596	Enhancement of all-trans retinoic acid-induced differentiation by pH-sensitive nanoparticles for solid tumor cells. 2014 , 14, 369-79		17
595	Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia. 2014 , 135, 2262-72		47
594	Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. 2014 , 93, 54-62		7
593	Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. 2014 , 32, 40-6		11
592	Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. <i>BMC Cancer</i> , 2014 , 14, 693	4.8	141

591	Transcriptional and Epigenetic Mechanisms Regulating Normal and Aberrant Blood Cell Development. 2014,	1
590	Transcriptional and Epigenetic Regulation in the Development of Myeloid Cells: Normal and Diseased Myelopoiesis. 2014, 223-245	
589	The extracts of Japanese willow tree species are effective forapoptotic desperation or differentiation of acute myeloid leukemia cells. 2014, 10, 125-31	3
588	Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. 2014, 27, 39-52	10
587	Translating the power of TCM into patients' hope. 2014, 8, 265-7	4
586	PML tumour suppression and beyond: therapeutic implications. 2014, 588, 2653-62	14
585	Contemporary treatment of APL. 2014, 9, 193-201	22
584	Molecular Testing in Cancer. 2014,	1
583	Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to tretinoin. 2014, 87, 55-63	27
582	cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis. 2014, 736, 115-23	13
581	Retinoic acid actions through mammalian nuclear receptors. 2014, 114, 233-54	84
580	Targeting cancer stem cells to suppress acquired chemotherapy resistance. <i>Oncogene</i> , 2014, 33, 4451-63.2	187
579	Pathway analysis for drug repositioning based on public database mining. 2014, 54, 407-18	34
578	p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. 2014, 21, 1852-61	45
577	Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. 2014, 74, 5386-96	20
576	The genomic and epigenomic landscapes of AML. 2014, 51, 259-72	11
575	Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years. 2014, 31, 136	2
574	Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. 2014, 111, 874-82	45

573	How I treat children and adolescents with acute promyelocytic leukaemia. 2014 , 164, 24-38	26
572	Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. 2014 , 324, 1-12	30
571	Expanding the computational toolbox for mining cancer genomes. 2014 , 15, 556-70	146
570	Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. 2014 , 100, 38-50	16
569	Ncor1 and Ncor2 play essential but distinct roles in zebrafish primitive myelopoiesis. 2014 , 243, 1544-53	9
568	Advanced progress on the relationship between RA and its receptors and malignant tumors. 2014 , 91, 271-82	12
567	Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. 2014 , 232, 4-15	83
566	All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade. 2014 , 59, 1750-60	56
565	Differentiation-stimulating potency of differentiated HL60 cells after drug treatment. 2014 , 68, 581-8	1
564	Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. 2014 , 38, 977-82	7
563	Coordinated regulation of the immunoproteasome subunits by PML/RAR α and PU.1 in acute promyelocytic leukemia. <i>Oncogene</i> , 2014 , 33, 2700-8	9.2 19
562	Analysis of gene profiles involved in the enhancement of all-trans retinoic acid-induced HL-60 cell differentiation by sesquiterpene lactones identifies asparagine synthetase as a novel target for differentiation-inducing therapy. 2014 , 44, 970-6	5
561	Understanding melanoma stem cells. 2015 , 2, 179-188	20
560	Epigenetic alterations in acute myeloid leukemias. 2015 , 282, 1786-800	29
559	Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. 2015 , 278, 627-42	24
558	From the first curative targeted cancer treatment to the implementation of the most extensive healthcare reform. 2015 , 278, 643-4	0
557	Cancer Pharmacogenomics. 2015 , 1, 164-191	
556	Blood's 70th anniversary: a rich history. <i>Blood</i> , 2015 , 126, 2529-30	2.2 1

555	Fighting against hematological malignancy in China: from unique system to global impact. 2015 , 58, 1183-90	7
554	CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid. 2015 , 14, 129	36
553	The function, regulation and therapeutic implications of the tumor suppressor protein, PML. 2015 , 5, 60	48
552	MDI 301 suppresses myeloid leukemia cell growth in vitro and in vivo without the toxicity associated with all-trans retinoic acid therapy. 2015 , 26, 763-73	
551	Solution and gas-phase acidities of all-trans (all-E) retinoic acid: an experimental and computational study. 2015 , 21, 11238-43	1
550	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. 2015 , 62, 629-36	34
549	Homocysteine Metabolism, Atherosclerosis, and Diseases of Aging. 2015 , 6, 471-505	57
548	The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy. 2015 , 4, 504-34	12
547	Retinoic acid liposome-hydrogel: preparation, penetration through mouse skin and induction of F9 mouse teratocarcinoma stem cells differentiation. 2015 , 51, 541-549	4
546	Targeting breast cancer using retinoic acid trifluoromethyl chalcone, a promising therapeutic strategy in the treatment of breast cancer. 2015 , 10,	
545	Persistent Hypoplastic Acute Promyelocytic Leukemia with a Novel Chromosomal Abnormality of 46, XY, t(15;17), t(9;11)(q13;p13). 2015 , 55, 71-6	
544	The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. 2015 , 16, 18252-69	9
543	An overview of targeted cancer therapy. 2015 , 5, 19	212
542	Additive Effects of Retinoic Acid (RA) and Bone Morphogenetic Protein 4 (BMP-4) Apoptosis Signaling in Retinoblastoma Cell Lines. 2015 , 10, e0131467	5
541	Retinoids: Nutritional, Cellular, and Pharmacological Roles of the Vitamin A Derivatives. 2015 ,	
540	Retinal Targets ALDH Positive Cancer Stem Cell and Alters the Phenotype of Highly Metastatic Osteosarcoma Cells. 2015 , 2015, 784954	9
539	A novel retinoic acid chalcone reverses epithelial-mesenchymal transition in prostate cancer cells. 2015 , 10, 288	0
538	Acute promyelocytic leukemia successfully treated also in elderly patients with significant comorbidities: a 20-year single-center experienc. 2015 , 62, 146-51	4

537	Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer. 2015 , 74, 373-412	39
536	Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia. 2015 , 43, 204-16	10
535	Retinoic acid-incorporated glycol chitosan nanoparticles inhibit the expression of Ezh2 in U118 and U138 human glioma cells. 2015 , 12, 6642-8	3
534	Acute Promyelocytic Leukaemia: From a Specific Translocation to Cure by Targeted Therapies. 2015 , 251-273	
533	Retinoic acid receptors: from molecular mechanisms to cancer therapy. 2015 , 41, 1-115	204
532	Detecting and targetting oncogenic fusion proteins in the genomic era. 2015 , 107, 111-29	24
531	Mitochondrial dependency in progression of acute myeloid leukemia. 2015 , 21, 41-8	32
530	Stress-induced NF- κ B activation differentiates promyelocytic leukemia cells to macrophages in response to all-trans-retinoic acid. 2015 , 27, 694-706	3
529	Distinguishing between cancer cell differentiation and resistance induced by all-trans retinoic acid using transcriptional profiles and functional pathway analysis. 2014 , 4, 5577	17
528	Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules identified through interrogation of the Connectivity Map database. 2015 , 14, 2578-89	11
527	Acute promyelocytic leukemia: where did we start, where are we now, and the future. 2015 , 5, e304	164
526	Retinoid Chemoprevention: Who Can Benefit?. 2015 , 1, 391-400	10
525	Direct and indirect targeting of MYC to treat acute myeloid leukemia. 2015 , 76, 35-46	27
524	RAI2: Linking Retinoic Acid Signaling with Metastasis Suppression. 2015 , 5, 466-8	6
523	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. 2015 , 168, 646-53	46
522	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. 2015 , 2, 563-71	36
521	Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. 2015 , 21, 457-66	166
520	Targeting Transcription Factors in Cancer. 2015 , 1, 53-65	149

519	Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon. 2015 , 15 Suppl, S80-4	1
518	Oxidative stress, redox regulation and diseases of cellular differentiation. 2015 , 1850, 1607-21	144
517	Reduced retinoids and retinoid receptors' expression in pancreatic cancer: A link to patient survival. 2015 , 54, 870-9	22
516	Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. 2015 , 9, 17-31	76
515	Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. 2015 , 37, 405-14	119
514	A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. 2015 , 31, 16-27	273
513	Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives. 2015 , 17,	31
512	All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. 2016 , 11, e0158760	20
511	In silico prediction of telomerase reverse transcriptase inhibitors using modified retinol for the treatment of arsenical cancer. 2016 , 9, 164	
510	RAR β mediates all-trans-retinoic acid-induced VEGF-C, VEGF-D, and VEGFR3 expression in lung cancer cells. 2016 , 40, 456-64	6
509	Association between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastoma. 2016 , 64, 963-76	24
508	miRNAs: mediators of ErbB family targeted therapy resistance. 2016 , 17, 1175-1187	6
507	NLS-RAR β modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway. 2016 , 14, 5495-5500	4
506	Current first- and second-line treatment options in acute promyelocytic leukemia. 2016 , 5, 105-118	5
505	Transcriptomics and proteomics in studies of induced differentiation of leukemia cells. 2016 , 10, 122-137	
504	Hematological Practice in Hong Kong and China. 2016 , 30, 445-56	1
503	Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia. 2016 , 140, 73-80	13
502	Current management of newly diagnosed acute promyelocytic leukemia. 2016 , 27, 1474-81	87

501	RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBP β /EBP β and PU.1. 2016 , 45, 68-74		14
500	Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. <i>Blood</i> , 2016 , 127, 29-41	2.2	278
499	Blood's 70th anniversary: arsenic--from poison pill to magic bullet. <i>Blood</i> , 2016 , 127, 1729-30	2.2	7
498	In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics. 2016 , 11, 1213-1222		2
497	Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol. 2016 , 38, 285-290		4
496	Multifunctional Silver Nanoparticles-Decorated Silica Functionalized with Retinoic Acid with Anti-Proliferative and Antimicrobial Properties. 2016 , 26, 1043-1052		5
495	Retinoylation (covalent modification by retinoic acid) of Rho-GDI β in the human myeloid leukemia cell line HL60 and its functional significance. 2016 , 1861, 2011-2019		9
494	Cancer Drug Discovery. 2016 ,		5
493	A High Throughput Phenotypic Screening reveals compounds that counteract premature osteogenic differentiation of HGPS iPS-derived mesenchymal stem cells. 2016 , 6, 34798		21
492	Pin1-Targeted Therapy for Systemic Lupus Erythematosus. 2016 , 68, 2503-13		17
491	Current standard treatment of adult acute promyelocytic leukaemia. 2016 , 172, 841-54		50
490	Galectin-12 inhibits granulocytic differentiation of human NB4 promyelocytic leukemia cells while promoting lipogenesis. 2016 , 100, 657-664		13
489	Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. 2016 , 7, 774-9		24
488	All-Trans-Retinoic-Acid Unmasking Hypercalcemia of Hyperparathyroidism. 2016 , 32, 41-5		3
487	The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. 2016 , 16, 463-78		140
486	DNA Repair in Despair-Vitamin D Is Not Fair. 2016 , 117, 1733-44		4
485	A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells. 2016 , 48, 734-46		11
484	Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. <i>Oncogene</i> , 2016 , 35, 4741-51	9.2	42

483	Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data. 2016 , 32, 1724-32	51
482	Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. 2016 , 114, 605-11	173
481	Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. 2016 , 95, 673-80	53
480	Characteristics of liver cancer stem cells and clinical correlations. 2016 , 379, 230-8	52
479	Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells. 2016 , 37, 323-9	5
478	Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium. 2017 , 166, 68-83	8
477	Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbCH8 expression in leukemia. 2017 , 128, 12-25	12
476	Frontline treatment of acute myeloid leukemia in adults. 2017 , 110, 20-34	68
475	Cancer reversion, a renewed challenge in systems biology. 2017 , 2, 49-58	9
474	Transcriptional Addiction in Cancer. 2017 , 168, 629-643	491
473	From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. 2017 , 46, 65-83	264
472	Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways. 2017 , 7, 43639	32
471	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. 2017 , 102, 381-391	42
470	Ex vivo all-trans retinoic acid modulates NO production and regulates IL-6 effect during rheumatoid arthritis: a study in Algerian patients. 2017 , 39, 87-96	7
469	Retinoic acid induces hypersegmentation and enhances cytotoxicity of neutrophils against cancer cells. 2017 , 182, 24-29	19
468	Chemotherapy for Leukemia. 2017 ,	2
467	Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis. 2017 , 22, 450-459	1
466	Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. 2017 , 52, 12-23	31

465	Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation. 2017 , 37, 2891-2896		7
464	Modulating epigenetic memory through vitamins and TET: implications for regenerative medicine and cancer treatment. 2017 , 9, 863-871		18
463	Acute Myeloid Leukaemia. 2017 , 135-248		
462	Combination of chemotherapy and cancer stem cell targeting agents: Preclinical and clinical studies. 2017 , 396, 103-109		54
461	Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents. 2017 , 1, 379-401		13
460	Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. 2017 , 31, 2347-2354		28
459	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase. <i>Cancer Cell</i> , 2017 , 31, 127-141	24.3	736
458	Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells. 2017 , 79, 295-301		34
457	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. 2017 , 26, 1648-1661		27
456	NLS-RAR β s a novel transcriptional factor. 2017 , 14, 7091-7098		
455	Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma. 2017 , 6, 2121-2130		9
454	Retinoic acid, CYP26, and drug resistance in the stem cell niche. 2017 , 54, 17-25		18
453	Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations. 2017 , 35, 2095-2102		16
452	Hitting the target in mutant AML. <i>Blood</i> , 2017 , 130, 693-694	2.2	3
451	All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion. 2017 , 7, 16481		8
450	Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?. 2017 , 37, 1052-1072		8
449	Acute Promyelocytic Leukemia: A Perspective. 2017 , 17, 543-544		9
448	Retinoic Acid Puts Hematopoietic Stem Cells Back To Sleep. 2017 , 21, 9-11		3

447	Generation of Human Hair Cells In Vitro: Is It All about How the Wnt Blows?. 2017 , 21, 11-12	2
446	Pathology and Molecular Pathology of Hematologic Malignancies. 2017 , 571-590	
445	Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. 2017 , 58, 1061-1067	14
444	Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE-independent mechanisms of gene expression. 2017 , 7, 16684	15
443	Effects of Pre- and Post-Administration of Vitamin A on the Growth of Refractory Cancers in Xenograft Mice. 2017 , 40, 486-494	4
442	A Paediatric Acute Promyelocytic Leukaemia Patient Harboring a Cryptic PML-RARA Insertion due to a Complex Structural Chromosome 17 Rearrangement. 2017 , 153, 181-189	2
441	CD90-Targeted Liposomes Increase the Therapeutic Efficacy of a Retinoic Acid Derivative in Pulmonary Carcinoma. 2017 , 02,	
440	Retinoic Acid Syndrome and Pseudotumor Cerebri in Patients with Acute Promyelocytic Leukemia. 2017 , 58, 745	
439	Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NF- κ B-dependent differentiation of AML cells. 2017 , 1, 2046-2057	22
438	Novel agents for the treatment of childhood leukemia: an update. 2017 , 10, 3299-3306	11
437	Aldehyde dehydrogenase 1A1 increases NADH levels and promotes tumor growth via glutathione/dihydrolipoic acid-dependent NAD reduction. 2017 , 8, 67043-67055	10
436	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. 2017 , 2017, 9620870	32
435	Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. 2017 , 10, 1585-1601	48
434	Growth Inhibition of Refractory Human Gallbladder Cancer Cells by Retinol, and Its Mechanism of Action. 2017 , 40, 495-503	6
433	The Use of Molecular Pathway Inhibitors in the Treatment of Osteosarcoma. 2017 ,	
432	Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt/NF- κ B signaling. 2017 , 38, 1517-1524	8
431	Recent advances in acute promyelocytic leukaemia. 2017 , 6, 1273	13
430	Insights from Large-Scale Cancer Genome Sequencing. 2018 , 2, 429-444	3

429	Naturally occurring compounds in differentiation based therapy of cancer. 2018 , 36, 1622-1632	18
428	Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia. 2018 , 59, 3013-3015	1
427	New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells. 2018 , 68, 98-104	2
426	ent-Jungermannone C Triggers Reactive Oxygen Species-Dependent Cell Differentiation in Leukemia Cells. 2018 , 81, 298-306	7
425	[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance]. 2018 , 143, 152-156	
424	Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. 2018 , 19, 160-174	46
423	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA mA Modification. 2018 , 22, 191-205.e9	476
422	A new option for remission induction in acute myeloid leukaemia. 2018 , 19, 156-157	3
421	History of Acute Promyelocytic Leukemia. 2018 , 1-16	1
420	Cure of APL Without Chemotherapy. 2018 , 133-151	
419	Molecular Targets of Treatment in APL. 2018 , 17-27	1
418	Molecular Genetics of APL. 2018 , 41-53	1
417	Early Death in APL. 2018 , 71-86	1
416	Prognostic Factors in APL. 2018 , 87-98	
415	First-Line Therapy for APL: Chemotherapy-Based Approach. 2018 , 99-112	
414	Management of Treatment-Related Complications in APL. 2018 , 257-267	
413	Acute Promyelocytic Leukemia. 2018 , 409-463	
412	PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan. 2018 , 23, 41-54	16

411	RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells. <i>Oncogene</i> , 2018 , 37, 352-362	9.2	3
410	Differentiation therapy revisited. 2018 , 18, 117-127		190
409	Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. 2018 , 100, 154-162		6
408	Combining accurate tumor genome simulation with crowdsourcing to benchmark somatic structural variant detection. 2018 , 19, 188		29
407	Cancer. 2018 , 6, i-76		
406	Toward the potential cure of leukemias in the next decade. 2018 , 124, 4301-4313		20
405	Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia. 2018 , 13, e0204850		4
404	Arsonolipids, pseudo arsonolipids, arsinolipids and arsonoliposomes: Preparations, biophysical, biochemical and biological aspects. 2018 , 17, 111-132		5
403	Extrinsic Regulation of Hematopoietic Stem Cells and Lymphocytes by Vitamin A. 2018 , 4, 282-290		1
402	DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid. 2018 , 10,		15
401	Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review. 2018 , 19,		28
400	Functional genomic landscape of acute myeloid leukaemia. 2018 , 562, 526-531		391
399	All-Trans Retinoic Acid Enhances Matrix Metalloproteinase 2 Expression and Secretion in Human Myeloid Leukemia THP-1 Cells. 2018 , 2018, 5971080		7
398	Acute Promyelocytic Leukemia. 2018 ,		2
397	Rare labial ulcer related to the use of all-trans retinoic acid in a patient with acute promyelocytic leukemia. 2018 , 38, 234-238		3
396	Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment. 2018 , 9, 651		36
395	Protagonist or antagonist? The complex roles of retinoids in the regulation of hematopoietic stem cells and their specification from pluripotent stem cells. 2018 , 65, 1-16		6
394	Development of novel silanol-based human pregnane X receptor (PXR) agonists with improved receptor selectivity. 2018 , 26, 4493-4501		4

393	Targeted therapy for fusion-driven high-risk acute leukemia. <i>Blood</i> , 2018 , 132, 1241-1247	2.2	16
392	Network Pharmacology in the Study of TCM Formulae. 2018 , 69-95		1
391	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. 2018 , 8, 530-538		27
390	Management of patients with acute promyelocytic leukemia. 2018 , 32, 1277-1294		50
389	What has traditional Chinese medicine delivered for modern medicine?. 2018 , 20, e4		89
388	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. 2018 , 1, 1-27		15
387	Combined Therapy in Cancer: The Non-coding Approach. 2018 , 12, 787-792		5
386	Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. 2018 , 63, 282-291		83
385	Differentiation Therapy Targeting the β -Catenin/CBP Interaction in Pancreatic Cancer. 2018 , 10,		27
384	Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. 2018 , 30, 375-383		14
383	Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy. 2018 , 36, 584		5
382	Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work?. 2019 , 30, 258-263		7
381	Factors Affecting Early Death and Survival of Patients With Acute Promyelocytic Leukemia Treated With ATRA-Based Therapy Regimens. 2019 , 19, e63-e70		9
380	Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. 2019 , 33, 358-370		14
379	RACK1 deficiency synergizes with all-trans retinoic acid to induce apoptosis in human acute promyelocytic leukemia cells. 2019 , 451, 155-163		2
378	Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia. 2019 , 14, e0221011		0
377	Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells. 2019 , 9, 9414		19
376	The c-Myc-regulated miR-17-92 cluster mediates ATRA-induced APL cell differentiation. 2019 , 15, 364-370		5

375	Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. 2019 , 9, 6745-6763	35
374	Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy. 2019 , 14, 7963-7973	8
373	Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005). 2019 , 36, 399-409	4
372	Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. 2019 , 20,	35
371	Formulation approaches for improved retinoids delivery in the treatment of several pathologies. 2019 , 143, 80-90	8
370	Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies. <i>Frontiers in Oncology</i> , 2019 , 9, 839	5-3 2
369	Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. 2019 , 41, 1010428319873749	2
368	Characterization of biopolymer-based systems obtained by spray-drying for retinoic acid controlled delivery. 2019 , 345, 758-765	14
367	The Pleiotropic Role of Retinoic Acid/Retinoic Acid Receptors Signaling: From Vitamin A Metabolism to Gene Rearrangements in Acute Promyelocytic Leukemia. 2019 , 20,	13
366	Leo Sachs. 14 October 1924–2 December 2013. 2019 , 66, 355-375	
365	Comparison of Three Processes for Parenteral Nanoemulsion Production: Ultrasounds, Microfluidizer, and Premix Membrane Emulsification. 2019 , 108, 2708-2717	16
364	Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/ β catenin oncogenic pathways. 2019 , 58, 1450-1464	16
363	Addressing the room for improvement in management of acute promyelocytic leukemia. 2019 , 102, 479-485	4
362	Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. 2019 , 62, 3590-3616	22
361	Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer. 2019 , 316, G632-G640	9
360	Identification of a point mutation PML-RAR α that alters PML body organization, dynamics and SUMOylation. 2019 , 511, 518-523	0
359	Measurable residual disease testing for personalized treatment of acute myeloid leukemia. 2019 , 127, 337-351	6
358	A 3D bioprinted hydrogel mesh loaded with all-trans retinoic acid for treatment of glioblastoma. 2019 , 854, 201-212	22

357	Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia. 2019 , 7, 33-65		24
356	Retinoids and oestrogenic endocrine disrupting chemicals in saline sewage treatment plants: Removal efficiencies and ecological risks to marine organisms. 2019 , 127, 103-113		13
355	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019 , 133, 1630-1643	2.2	219
354	Methionine Dependence of Cancer and Aging. 2019 ,		1
353	Homocysteine, Thioretinaco Ozonide, and Oxidative Phosphorylation in Cancer and Aging: A Proposed Clinical Trial Protocol. 2019 , 1866, 285-310		1
352	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. 2019 , 2019, 5245034		54
351	Prolonged Myelosuppression due to Progressive Bone Marrow Fibrosis in a Patient with Acute Promyelocytic Leukemia. 2019 , 2019, 1616237		3
350	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. 2019 , 64, 238-247		12
349	Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. 2019 , 9, 16775		5
348	Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist. 2019 , 5, e02849		1
347	Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms. 2019 , 7, 322		13
346	Precision Cancer Medicine. 2019 ,		
345	Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy. 2019 , 26, 1566-1581		19
344	Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia. 2019 , 60, 711-719		3
343	Cancer and AIDS. 2019 ,		
342	Curative strategies in APL. 2019 , 56, 131-138		5
341	Synergistic antitumor activity of oridonin and valproic acid on HL-60 leukemia cells. 2019 , 120, 5620-5627		4
340	The success and the challenge of all-trans retinoic acid in the treatment of cancer. 2019 , 59, S71-S80		32

339	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. 2020 , 20, 105-113	1
338	Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. 2020 , 20, e382-e391	3
337	Upregulation of amphiregulin by retinoic acid and Wnt signalling promotes liver cancer cell proliferation. 2020 , 235, 1689-1699	2
336	ABC-transporters and drug efflux in hematologic cancers. 2020 , 149-195	1
335	Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial. 2020 , 21, 7	1
334	A two-pronged anti-leukemic agent based on a hyaluronic acid-green tea catechin conjugate for inducing targeted cell death and terminal differentiation. 2019 , 8, 497-505	6
333	Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?. 2020 , 126, 256-259	0
332	Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma. 2020 , 146, 41-53	11
331	High CXCR2 expression predicts poor prognosis in adult patients with acute myeloid leukemia. 2020 , 11, 2040620720958586	4
330	Development of differentiation modulators and targeted agents for treating neuroblastoma. 2020 , 207, 112818	5
329	The synergistic role of Pu.1 and Fms in zebrafish osteoclast-reducing osteopetrosis and possible therapeutic strategies. 2020 , 47, 535-546	1
328	Therapeutic Approaches for Acute Promyelocytic Leukaemia: Moving Towards an Orally Chemotherapy-Free Era. <i>Frontiers in Oncology</i> , 2020 , 10, 586004	5-3 4
327	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. 2020 , 11, 1590	17
326	Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. 2020 , 111, 3367-3378	5
325	Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors. 2020 , 55, 544-557.e6	7
324	All-Trans Retinoic Acid Rescues the Tumor Suppressive Role of RAR- β by Inhibiting LncHOXA10 Expression in Gastric Tumorigenesis. 2021 , 73, 2065-2077	4
323	Emerging Cancer Epigenetic Mechanisms Regulated by All-Trans Retinoic Acid. 2020 , 12,	7
322	Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia. 2020 , 9,	3

321	Induction of differentiation of the acute myeloid leukemia cell line (HL-60) by a securinine dimer. 2020 , 6, 123	3
320	IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells. 2020 , 4, 6368-6383	
319	Cost-effectiveness of the regimen proposed by the International Consortium on Acute Promyelocytic Leukemia for the treatment of newly diagnosed patients with Acute Promyelocytic Leukemia. 2021 , 43, 476-481	1
318	Second Primary Malignancy after Acute Promyelocytic Leukemia: A Population-Based Study. 2020 , 12,	1
317	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. 2020 , 9,	4
316	Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. 2020 , 112, 349-360	
315	Histone deacetylase inhibitor based prodrugs. 2020 , 203, 112628	8
314	The role of circular RNAs in hematological malignancies. 2020 , 112, 4000-4008	9
313	PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy. 2020 , 6, 889-906	11
312	Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia. 2020 , 11, 102	15
311	ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. <i>Oncogene</i> , 2020 , 39, 3195-3205	9.2 9
310	Current understanding of potential ecological risks of retinoic acids and their metabolites in aquatic environments. 2020 , 136, 105464	11
309	Advances in Pediatric Acute Promyelocytic Leukemia. 2020 , 7,	9
308	Redifferentiation therapeutic strategies in cancer. 2020 , 25, 731-738	6
307	JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL). 2020 , 111, 747-760	1
306	Suppression of cancer stem cells. 2020 , 365-398	
305	Clinical significance of increased PML-RARa transcripts after induction therapy for acute promyelocytic leukaemia. 2020 , 52, 233-238	0
304	Progresses and emerging trends of arsenic research in the past 120 years. 2021 , 51, 1306-1353	9

303	Interaction of Tretinoin and Nimesulide with Amylose Matrices. 2021 , 73, 2000054	4
302	Outcomes for Patients With Acute Promyelocytic Leukemia in South Africa. 2021 , 21, e348-e352	0
301	The ecology of cancer differentiation therapy. 2021 , 511, 110552	2
300	Drug repurposing for cancer therapy, easier said than done. 2021 , 68, 123-131	11
299	Management of Acute Promyelocytic Leukemia. 2021 , 177-197	
298	Potential therapeutic uses of rexinoids. 2021 , 91, 141-183	4
297	Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. 2021 , 27, 1893-1903	3
296	Understanding how retinoic acid derivatives induce differentiation in non-M3 acute myelogenous leukemia. 2021 , 106, 927-928	
295	A Case of Acute Promyelocytic Leukemia With Retinal Hemorrhages Beneath Internal Limiting Membrane During Clinical Remission. 2021 , 13, e13387	0
294	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. 2021 , 96, 735-746	2
293	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. 2021 , 127, 1186-1207	18
292	The Mechanism of Neurite Outgrowth Induction by Novel Synthetic Retinobenzoic Acids.	
291	Critical regulatory levels in tumor differentiation: Signaling pathways, epigenetics and non-coding transcripts. 2021 , 43, e2000190	
290	Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?. 2021 , 62, 1949-1957	2
289	Ampelopsin Inhibits Cell Proliferation and Induces Apoptosis in HL60 and K562 Leukemia Cells by Downregulating AKT and NF- κ B Signaling Pathways. 2021 , 22,	5
288	Precision medicine in myeloid malignancies. 2021 ,	5
287	Vitamin A as a Cause of Pseudotumor Cerebri Syndrome: Not to Be Forgotten. 2021 , 41, e403-e406	0
286	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. 2021 , 6, 203-215	0

285	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. 2021 , 14, 101025	3
284	Inhibition of retinoic acid receptor β phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3. 2021 , 40, 141	3
283	Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case. 2021 , 10781552211007889	2
282	Changes in the levels of β actinin-4 in differentiating human myeloid leukemia cells induced by retinoic acid. 2021 , 1868, 118968	1
281	Current views on the genetic landscape and management of variant acute promyelocytic leukemia. 2021 , 9, 33	8
280	Growth Inhibitory Effects of Ester Derivatives of Menahydroquinone-4, the Reduced Form of Vitamin K, on All-Trans Retinoic Acid-Resistant HL60 Cell Line. 2021 , 13,	1
279	Retinal toxicities of systemic anticancer drugs. 2021 ,	1
278	Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. 2021 , 5, 38	4
277	Induced lineage promiscuity undermines the efficiency of all-trans-retinoid-acid-induced differentiation of acute myeloid leukemia. 2021 , 24, 102410	
276	MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. 2021 , 28, 3235-3250	1
275	Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes. 2021 , 21, 638-648	0
274	Acute promyelocytic leukemia current treatment algorithms. 2021 , 11, 123	15
273	Concomitant central venous sinus thrombosis and subdural hematoma in acute promyelocytic leukemia: middle meningeal artery embolization enables safe anticoagulation. Illustrative case. 2021 , 1,	
272	Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Krüppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis. 2021 , 194, 598-603	0
271	Retinoic Acid-Induced Gene G(RIG-G) as a Novel Monitoring Biomarker in Leukemia and Its Clinical Applications. 2021 , 12,	1
270	Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan. 2021 , 100, 2613-2619	1
269	RAR α activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway. <i>Blood</i> , 2021 ,	2.2 1
268	Trametinib enhances ATRA-induced differentiation in AML cells. 2021 , 1-12	0

267	Modulating cell differentiation in cancer models. 2021 , 49, 1803-1816	0
266	KDM5A suppresses PML-RAR α target gene expression and APL differentiation through repressing H3K4me2. 2021 , 5, 3241-3253	0
265	Drug treatment options for acute promyelocytic leukemia. 2021 , 1-11	2
264	Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia. <i>Blood</i> , 2021 ,	2.2 1
263	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. 2021 , 21, 580-597	7
262	A splicing factor phosphorylated by protein kinase A is increased in HL60 cells treated with retinoic acid. 2022 , 1869, 119142	1
261	Variants in ALDH1A2 reveal an anti-inflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis.	
260	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. 2021 , 22,	2
259	Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia. 2021 , 26, 271-276	
258	Analytics methods and tools for integration of biomedical data in medicine. 2021 , 113-129	
257	All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling. 2021 , 41, 51-61	0
256	New chemotherapeutic agents for breast cancer. 1994 , 74, 1164-1176	11
255	In vivo and in vitro effects of TGF-beta 1 on normal and neoplastic haemopoiesis. 1991 , 157, 212-27; discussion 227-31	6
254	Novel biologic approaches to hematologic malignancies. 1999 , 99, 275-306	2
253	Current approaches to acute promyelocytic leukemia. 1999 , 99, 125-53	4
252	Retinoids: Concepts for Separation of Desirable and Undesirable Effects in the Treatment or Prevention of Cancer. 1996 , 127-146	3
251	Retinoids in clinical cancer therapy. 1996 , 87, 305-42	9
250	PML nuclear bodies and other TRIM-defined subcellular compartments. 2012 , 770, 39-58	10

249	Vitamin A and Immunity. 1993 , 197-216	2
248	All trans retinoic acid as a targeting drug for differentiation therapy in acute promyelocytic leukemia. 1993 , 64, 1-13	2
247	Oncogenes and tumor suppressor genes. 1992 , 63, 1-13	3
246	Cancer. 1996 , 129-161	1
245	Micronutrients as Intermediate Biomarkers in Chemotherapy and Enhancement for Cancer Treatments. 2001 , 55-72	1
244	Characterization of Natural Product Chemopreventive Agents. 2005 , 3-37	23
243	Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia. 2008 , 161-187	3
242	Vitamin A. 2010 , 335-356	8
241	Clinical Interpretation. 2019 , 33-48	2
240	Monoclonal antibody therapy of APL. 2007 , 313, 205-19	3
239	The design of selective and non-selective combination therapy for acute promyelocytic leukemia. 2007 , 313, 245-69	10
238	The Retinoids: Cancer Therapy and Prevention Mechanisms. 1999 , 301-322	17
237	Retinoids and Differentiation of Normal and Malignant Hematopoietic Cells. 1999 , 277-300	2
236	Retinoic Acid in Myeloid Differentiation and Acute Promyelocytic Leukemia (APL). 2003 , 52-61	2
235	Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. 1997 , 220, 81-112	34
234	Chemotherapy of the Leukaemias. 1990 , 5-77	2
233	Myeloid Differentiation Mediated Through New Potent Retinoids and Vitamin D3 Analogs. 1996 , 439-450	1
232	Clinical Pharmacology of the Retinoids. 1995 , 55-66	1

231	Clonal Deletion, A Novel Strategy of Cancer Control that Falls Between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer. 2000 , 97-103	2
230	Cancer: Clinical Background and Key Challenges. 2011 , 29-93	1
229	The genetics of lung cancer. 1995 , 21-43	5
228	Retinoid receptors. 1993 , 48, 99-121	89
227	Acute Myeloid Leukemia in Adults. 2008 , 2215-2234	1
226	Cytogenetic and Molecular Pathology of Pediatric Cancer. 2009 , 99-171	1
225	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402	1
224	Retinoylation of HL-60 proteins. Comparison to labeling by palmitic and myristic acids.. 1990 , 265, 19158-19162,1	31
223	Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids.. 1994 , 269, 21440-21447	70
222	Retinoylation of vimentin in the human myeloid leukemia cell line HL60.. 1994 , 269, 5913-5917	33
221	Retinoic Acid Acylation (Retinoylation) of a Nuclear Protein in the Human Acute Myeloid Leukemia Cell Line HL60. 1989 , 264, 5159-5163	72
220	Transcriptional regulation and increased functional expression of the inositol trisphosphate receptor in retinoic acid-treated HL-60 cells.. 1992 , 267, 20959-20964	20
219	Inhibition of mitogen-induced c-fos expression in melanoma cells by retinoic acid involves the serum response element.. 1992 , 267, 19971-19977	19
218	Acute Promyelocytic Leukemia: New Insights into Diagnosis and Therapy. 1993 , 7, 109-138	10
217	Differentiation Therapy. 1992 , 6, 687-706	20
216	Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies. 2001 , 42, 1265-1273	12
215	Effect of 13-cis-retinoic acid with neoadjuvant chemotherapy in patients with squamous cervical carcinoma. 1996 , 19, 442-4	1
214	Short-term intensive consolidation therapy after all-trans retinoic acid in acute promyelocytic leukemia. 1999 , 22, 294-7	2

213	Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index.		0
212	Targeting of cancer stem cells by differentiation therapy. 2020 , 111, 2689-2695		13
211	Pan-cancer analyses of the nuclear receptor superfamily. 2015 , 2,		31
210	Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). 1990 , 10, 2154-2163		66
209	Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. 1992 , 12, 800-810		22
208	Formation of retinoid X receptor homodimers leads to repression of T3 response: hormonal cross talk by ligand-induced squelching. 1993 , 13, 7698-7707		39
207	PML, a growth suppressor disrupted in acute promyelocytic leukemia. 1994 , 14, 6858-6867		79
206	East meets West: an herbal tea finds a receptor. 2004 , 113, 23-5		28
205	Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. 2005 , 115, 2924-33		35
204	CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. 1999 , 103, 1399-408		152
203	CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. 2007 , 117, 1412-21		29
202	Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. 2016 , 126, 4460-4468		30
201	Ham-Wasserman Lecture. 2003 , 2003, 1-13		1
200	Mitochondrial Antisense RNA for Cytochrome C Oxidase (MARCO) Can Induce Morphologic Changes and Cell Death in Human Hematopoietic Cell Lines. <i>Blood</i> , 1997 , 90, 4567-4577	2.2	22
199	Mitochondrial Antisense RNA for Cytochrome C Oxidase (MARCO) Can Induce Morphologic Changes and Cell Death in Human Hematopoietic Cell Lines. <i>Blood</i> , 1997 , 90, 4567-4577	2.2	2
198	Treatment With a New Synthetic Retinoid, Am80, of Acute Promyelocytic Leukemia Relapsed From Complete Remission Induced by All-trans Retinoic Acid. <i>Blood</i> , 1997 , 90, 967-973	2.2	4
197	An Allelic Association Implicates Myeloperoxidase in the Etiology of Acute Promyelocytic Leukemia. <i>Blood</i> , 1997 , 90, 2730-2737	2.2	6
196	Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. <i>Blood</i> , 1998 , 91, 4300-4310	2.2	17

195	Restoration of Retinoid Sensitivity by MDR1 Ribozymes in Retinoic Acid Resistant Myeloid Leukemic Cells. <i>Blood</i> , 1998 , 91, 2452-2458	2.2	1
194	Trivalent Antimonials Induce Degradation of the PML-RAR α Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells. <i>Blood</i> , 1998 , 92, 4308-4316	2.2	5
193	Mutations in the E-Domain of RAR α Portion of the PML/RAR α Chimeric Gene May Confer Clinical Resistance to All-trans Retinoic Acid in Acute Promyelocytic Leukemia. <i>Blood</i> , 1998 , 92, 374-382	2.2	8
192	Impaired Granulocytic Differentiation In Vitro in Hematopoietic Cells Lacking Retinoic Acid Receptors α and β <i>Blood</i> , 1998 , 92, 607-615	2.2	9
191	Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RAR α Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy. <i>Blood</i> , 1998 , 92, 1172-1183	2.2	6
190	Targeting of PML/RAR α Is Lethal to Retinoic Acid Resistant Promyelocytic Leukemia Cells. <i>Blood</i> , 1998 , 92, 1758-1767	2.2	38
189	Targeting of PML/RAR α Is Lethal to Retinoic Acid Resistant Promyelocytic Leukemia Cells. <i>Blood</i> , 1998 , 92, 1758-1767	2.2	6
188	Incidence, Clinical Features, and Outcome of All-Trans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1998 , 92, 2712-2718	2.2	4
187	Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial. <i>Blood</i> , 1999 , 93, 4131-4143	2.2	4
186	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. <i>Blood</i> , 1999 , 93, 1308-1318	2.2	14
185	1,25-Dihydroxyvitamin D3 Induces Differentiation of a Retinoic Acid Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated With Expression of p21WAF1/CIP1 and p27KIP1. <i>Blood</i> , 1999 , 93, 2225-2233	2.2	5
184	Chromatin Remodeling and Leukemia: New Therapeutic Paradigms. <i>Blood</i> , 1999 , 94, 417-428	2.2	15
183	All-Trans Retinoic Acid Delays the Differentiation of Primitive Hematopoietic Precursors (lin $^{-}$ kit+Sca-1+) While Enhancing the Terminal Maturation of Committed Granulocyte/Monocyte Progenitors. <i>Blood</i> , 1999 , 94, 483-495	2.2	5
182	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 1192-1200	2.2	8
181	Blood: New designs for a new millennium. <i>Blood</i> , 2000 , 95, 1-6	2.2	1
180	HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. <i>Blood</i> , 2000 , 96, 3553-3559	2.2	4
179	Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid sensitive and resistant acute promyelocytic leukemia cells. <i>Blood</i> , 2000 , 96, 2233-2239	2.2	1
178	Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation. <i>Blood</i> , 2000 , 96, 2262-2268	2.2	1

177	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. <i>Blood</i> , 2002 , 99, 1014-1022	2.2	4
176	Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma. 2020 , 15, 113		8
175	Ret finger protein is a normal component of PML nuclear bodies and interacts directly with PML. 1998 , 111, 1319-1329		67
174	ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. 2000 , 113, 4577-4585		109
173	Cell plasticity in cancer cell populations. 2020 , 9,		14
172	Retinoic acid signaling plays a restrictive role in zebrafish primitive myelopoiesis. 2012 , 7, e30865		15
171	Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells. 2015 , 10, e0130343		14
170	Retinoid- and sodium-butyrate-induced decrease in heat shock protein 70 membrane-positive tumor cells is associated with reduced sensitivity to natural killer cell lysis, growth delay, and altered growth morphology. 2005 , 10, 136-46		13
169	All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. 1996 , 1, 305-314		33
168	The Myelodysplastic Syndromes. 1997 , 2, 28-39		3
167	[Transcriptomics and proteomics in studies of induced differentiation of leukemia cells]. 2015 , 61, 529-44		1
166	Opposing roles of ICAT and Wnt/ β -catenin signaling in NSC67657-induced monocytic differentiation. 2017 , 8, 69924-69933		2
165	Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells. 2018 , 9, 33138-33148		6
164	Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. 2016 , 7, 43689-43702		4
163	Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide. 2020 , 20, 115-129		4
162	The Antitumoral Activity of Zataria Multiflora Methanolic Extract on Acute Promyelocytic Leukemia Cell Line; NB4. 2018 , 26, 43-47		3
161	Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. 2011 , 54, 95-105		9
160	The effect pathway of retinoic acid through regulation of retinoic acid receptor alpha in gastric cancer cells. 2001 , 7, 662-6		21

- 159 The emerging role of myeloid-derived suppressor cells in radiotherapy. **2020**, 38, 1-10 16
- 158 Molecularly-targeted Strategy and NF- κ B in lymphoid malignancies. **2013**, 53, 185-95 12
- 157 Automated analysis of differentiation-induced leukemic cells during all-trans retinoic Acid therapy of acute promyelocytic leukemia. **2003**, 127, e4-10 3
- 156 New insights into 4-amino-2-tri-fluoromethyl-phenyl ester inhibition of cell growth and migration in the A549 lung adenocarcinoma cell line. **2013**, 14, 7265-70 17
- 155 A novel all-trans retinoid acid derivative N-(3-trifluoromethyl- phenyl)- retinamide inhibits lung adenocarcinoma A549 cell migration through down-regulating expression of myosin light chain kinase. **2014**, 15, 7687-92 11
- 154 The cure of leukemia through the optimist's prism. **2021**, 128, 240 2
- 153 A Novel Acute Promyelocytic Leukemia Model: From Cell to Murine System. **2000**, 133-142
- 152 Treatment of acute promyelocytic leukemia with all-trans retinoic acid. **2000**, 231-240
- 151 Therapeutic uses of retinoic acid receptor antagonists and inverse agonists. **2000**, 279-290
- 150 Autologous Stem Cell Transplantation in Acute Promyelocytic Leukemia Patients Achieving a Second Complete Remission. **2000**, 239-247
- 149 Retinoid Receptors. **2001**, 245-295 1
- 148 Severe Laryngeal Edema in Acute Promyelocytic Leukemia under All-Trans Retinoic Acid. **2001**, 592-595
- 147 Growth Inhibition of Pancreatic Cancer Cell Lines by Ligand Activation of Nuclear Hormone Receptors Through Up-Expression of WAF1/CIP1/p21. **2001**, 147-152
- 146 Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?. **2001**, 54-60
- 145 APL Biology. **2001**, 557-561
- 144 Regulation of Bcl-2 Expression in Glioma Cells by All-trans Retinoic Acid. **2002**, 14, 87-95
- 143 Retinoid-Induced Apoptosis in Hepatocellular Carcinoma: A Molecular Basis for "Clonal Deletion" Therapy. **2002**, 33-39
- 142 Les r cepteurs nucl aires de l'acide r ino ique : une base mol culaire commune pour le cancer du foie et les leuc mies aigu s promy oblastaires. **2002**, 186, 751-757

- 141 Growth and differentiation factors as cancer therapeutics. **2003**, 499-542
- 140 Screening trial of cancer chemopreventive agent by using combination of DNA chip technology and Cell Signaling Network DataBase (CSNDB). **2003**, 88-99
- 139 Akute myeloische Leukämien. **2003**, 312-350
- 138 Acute promyelocytic leukemia. **2004**, 657-668
- 137 PML/RARA and RARA Fish in Follow-up of Acute Promyelocytic Leukemia. **2004**, 1021-1025
- 136 Gene Expression Analysis in Pharmacogenetics and Pharmacogenomics. **2005**, 389-412
- 135 Akute myeloische Leukämie (AML). **2006**, 2605-2645
- 134 APL: A Classic Tale of Bench to Bedside. **2007**, 193-228
- 133 Differentiation Therapy in AML. **2007**, 293-312
- 132 Gene Expression Profiling of the Leukemias: Oncogenesis, Drug Responsiveness, and Prediction of Clinical Outcome. **2009**, 1-19
- 131 The Future of Molecular Neuro-Oncology. **2009**, 3201-3228
- 130 Targeted Approaches to Drug Development. **2009**, 57-98
- 129 The Stem State in Cancer. **2009**, 217-244
- 128 Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes. **2010**, 155-176
- 127 Acute Promyelocytic Leukaemia. **2010**, 83-108
- 126 Effects of Natural and Synthetic Retinoids on the Differentiation and Growth of Squamous Cancers. **2011**, 261-282
- 125 MicroRNAs in Leukemia. **2011**, 269-285
- 124 Acute Leukaemia: Integration of Morphological, Immunophenotypic and Genetic Information and the WHO Classification. 114-218

123 Anticancer Effects of Intermittent Hypoxia in Acute Myeloid Leukemia. **2012**, 229-238

122 Novel Targeted Therapeutics for Acute Myeloid Leukemia. **2012**, 315-348

121 Targeting the Prostate Stem Cell for Chemoprevention. **2013**, 127-148

120 Pharmacogenomics in Molecular Oncology. **2014**, 405-421

119 Recent Advances in Chemotherapy for Certain Leukaemias. **1990**, 187-193

118 Cancer. **1992**, 121-156

117 Regulation of gene expression by thyroid hormones and retinoic acid. **1992**, 14, 185-209

116 Probing the Pathophysiology of Leukemic Response by Premature Chromosome Condensation. **1992**, 185-189

115 Akute Leukämien. **1992**, 223-282

114 Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. **1992**, 12, 3743-3749

16

113 New Chemotherapeutic Agents: A Selection of Some of the Most Promising New Drugs. **1993**, 335-346

112 Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation. **1993**, 105-114

1

111 ATRA Therapy in Acute Promyelocytic Leukemia a Model for Differentiation Therapy. **1993**, 99-108

110 Molecular Mechanisms of Thyroid Hormone and Retinoic acid Action. **1994**, 193-211

109 ALL Transretinoic Acid Followed by Intensive Chemotherapy in Newly Diagnosed Acute Promyelocytic Leukemia: A Pilot Study on 27 Cases. **1994**, 606-608

108 Treatment Strategy of Acute Promyelocytic Leukemia Using All Trans Retinoic Acid. **1994**, 129-132

107 SCID-hu Mice as a Model for the Study of Human Malignancies. **1995**, 157-170

106 Akute myeloische Leukämie. **1995**, 111-123

- 105 Clinical and Molecular Advances in Acute Promyelocytic Leukaemia. **1995**, 73-88
- 104 Acute Promyelocytic Leukemia: Advantage of A-Trans Retinoic Acid (ATRA) over Conventional Chemotherapy. **1996**, 415-419
- 103 Molecular Basis for Retinoic Acid Effects in Acute Promyelocytic Leukemia. **1996**, 409-414
- 102 Clinical Aspects of Acute Promyelocytic Leukemia and Response to Retinoid Therapy. **1996**, 539-576
- 101 Retinoic acid receptors in hematopoiesis. **1996**, 211, 7-15 5
- 100 Differentiation of Malignant Cells as a Therapeutic Approach. **1996**, 285-293
- 99 Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemia. **1996**, 211, 269-78 7
- 98 Molecular Biology of Acute Promyelocytic Leukemia. **1996**, 577-605
- 97 Differentiation Therapy of Acute Promyelocytic Leukemia. **1996**, 29-37
- 96 Responses of Leukemia Cells to Hematopoietic Growth Factors. **1996**, 303-319
- 95 How Does Basic Research in Cancer and AIDS Approach the Concern for Quality of Life?. **1997**, 17-35
- 94 Akute myeloische Leukämie (AML, ANLL). **1997**, 3-32
- 93 Results of All-Trans Retinoic Acid Treatment in Acute Promyelocytic Leukemia (European Experience). **1997**, 782-786
- 92 Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)₂ Vitamin D₃, and Granulocyte-Macrophage Colony-Stimulating Factor. *Blood*, **1997**, 90, 4578-4587 2.2
- 91 Therapeutic manipulation of apoptosis in cancer and neurological disease. **1998**, 281-303
- 90 All-Trans Retinoic Acid (ATRA) Combined with Double Induction Strategy in Acute Promyelocytic Leukemia (APL). Preliminary Results. **1998**, 881-885
- 89 Liposome-Mediated Delivery of Retinoids. **1998**, 87-94
- 88 Akute myeloische Leukämie. **1998**, 165-179

- 87 Clinical Pharmacology of Vitamin A and Retinoids. **1998**, 31-38
- 86 Phosphorylation of BCL-2 After Exposure of Human Leukemic Cells to Retinoic Acid. *Blood*, **1998**, 92, 1768-1775 2.2 1
- 85 Hematological Disorders. **1999**, 263-294
- 84 CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate Into Dendritic Cells. *Blood*, **1999**, 94, 2048-2055 2.2
- 83 Preparation and antitumor activity of a tamibarotene-furoxan derivative. **2014**, 15, 6343-7 1
- 82 Targeting PML-RAR α with Retinoids. **2015**, 489-507
- 81 PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response. **2015**, 461-475
- 80 Molecular Targeted Anticancer Drugs. **2016**, 175-238
- 79 PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide. **2016**, 17, 1999-2006 1
- 78 Studies on Arsenic and Human Health. **2017**, 37-66
- 77 Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene. **2017**, 183-211 1
- 76 Clinico Hematological Profile of Acute Promyelocytic Leukemia. **2017**, 4, 0
- 75 Combining accurate tumour genome simulation with crowd-sourcing to benchmark somatic structural variant detection. 1
- 74 Therapy of Cancer and Retroviral Diseases. **2019**, 65-158 1
- 73 Analysis of post-translational modification by electrophoresis. New developments on the functional analysis of retinoylated proteins. **2019**, 63, 35-39
- 72 [Chemotherapy-Free Treatment of Hematological Neoplasias: Dream or Reality?]. **2019**, 108, 411-418
- 71 Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.
- 70 The ecology of cancer differentiation therapy.

69	Limiting Self-Renewal of the Basal Compartment Induces Differentiation and Alters Evolution of Mammary Tumors.		1
68	Roscovitine enhances all- retinoic acid (ATRA)-induced nuclear enrichment of an ensemble of activated signaling molecules and augments ATRA-induced myeloid cell differentiation. 2020 , 11, 1017-1036		4
67	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , 2021 ,	2.2	2
66	Arsenic Trioxide and Leukemia. 2005 , 251-272		
65	Akute myeloische Leukämie. 239-250		
64	Diagnosis and Classification of the Acute Myeloid Leukemias (with Discussion of the Role of the Myelodysplastic Syndromes in AML Pathogenesis). 2008 , 21-46		1
63	Clinical Presentation, Diagnosis, and Classification of Acute Myeloid Leukemia. 2021 , 11-55		
62	Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update. 2021 , 22,		4
61	A master of all trades - linking retinoids to different signalling pathways through the multi-purpose receptor STRA6. 2021 , 7, 358		1
60	Diet-Induced Adipocyte Browning. 2021 , 353-381		
59	To B (Bone Morphogenic Protein-2) or Not to B (Bone Morphogenic Protein-2): Mesenchymal Stem Cells May Explain the Protein's Role in Osteosarcomagenesis. 2021 , 9, 740783		0
58	Targeting CAMKK2 and SOC Channels as a Novel Therapeutic Approach for Sensitizing Acute Promyelocytic Leukemia Cells to All-Trans Retinoic Acid.. 2021 , 10,		1
57	Transcription Factor Activation Profiles (TFAP) identify compounds promoting differentiation of Acute Myeloid Leukemia cell lines.. 2022 , 8, 16		
56	Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and $\alpha 4 \beta 7$ Integrin and Direct Their Migration .. 2022 , 13, 746484		2
55	The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition.. 2022 , 1-27		0
54	Clonal diversification and histogenesis of malignant germ cell tumours.		1
53	Functions, mechanisms, and therapeutic implications of METTL14 in human cancer.. 2022 , 15, 13		4
52	The Integration of a Hospitalist.. 2022 , 11, 21649561211073879		

51	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears.. <i>BMC Cancer</i> , 2022 , 22, 201	4.8	1
50	All-Trans Retinoic Acid Prevents the Progression of Gastric Precancerous Lesions by Regulating Disordered Retinoic Acid Metabolism.. 2022 , 1-12		
49	The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.. 2022 , 101, 1049		1
48	PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38 signalling.. <i>Oncogene</i> , 2022 ,	9.2	0
47	Histone Deacetylase Inhibitor I3 Induces Differentiation of Acute Myeloid Leukemia Cells with T(8;21) or MLL Gene Translocation and Leukemic Stem-Like Cells. <i>SSRN Electronic Journal</i> ,	1	
46	A phenogenetic axis that modulates clinical manifestation and predicts treatment outcome in primary myeloid neoplasms. <i>Cancer Research Communications</i> ,		
45	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.. <i>Frontiers in Oncology</i> , 2022 , 12, 871590	5.3	1
44	Image_1.pdf. 2019 ,		
43	Evolving of Treatment Paradigms and Challenges in Acute Promyelocytic Leukaemia: A Real-World Analysis of 1105 Patients Over the Last Three Decades. <i>SSRN Electronic Journal</i> ,	1	
42	Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022 , 2022, 1-8	2.3	
41	Vitamin D Derivatives in Acute Myeloid Leukemia: The Matter of Selecting the Right Targets. <i>Nutrients</i> , 2022 , 14, 2851	6.7	2
40	Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3. <i>BMC Cancer</i> , 2022 , 22,	4.8	
39	Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1003-1009	6.1	5
38	Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. <i>Cancer Cell</i> , 2022 ,	24.3	4
37	Chronicle of a discovery: the retinoic acid receptor. 2022 ,		1
36	Clonal diversification and histogenesis of malignant germ cell tumours. 2022 , 13,		0
35	Treatment for relapsed acute promyelocytic leukemia.		0
34	p53 as a unique target of action of cisplatin in acute leukaemia cells.		

33	Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias.	1
32	Updates and Original Case Studies Focused on the NMR-Linked Metabolomics Analysis of Human Oral Fluids Part II: Applications to the Diagnosis and Prognostic Monitoring of Oral and Systemic Cancers. 2022 , 12, 778	1
31	Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades. 2022 , 25, 101522	0
30	Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells. 2022 , 2022, 1-13	1
29	Clinical implications and genetical insights of SOX6 expression in acute myeloid leukemia.	0
28	Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells. 13,	0
27	Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies. 2022 , 12,	1
26	Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives.	3
25	Differentiation Therapy. 1-19	0
24	Co-encapsulation of retinoic acid, curcumin and resveratrol by spray-drying of alginate sodium-based emulsions and ethyl cellulose-based solutions: Impact on the co-delivery profiles. 2022 ,	0
23	Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms. 1-21	0
22	Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia. 2023 ,	0
21	An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). 2022 , 12,	1
20	Variants in ALDH1A2 reveal an anti-inflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis. 2022 , 14,	0
19	Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia. 2022 , 12,	0
18	Ultrafast prediction of somatic structural variations by filtering out reads matched to pan-genome k-mer sets.	0
17	Retinoic acid metabolism in cancer: potential feasibility of retinoic acid metabolism blocking therapy.	0
16	Methylthioacetic acid, a derivative of aroma compounds from <i>Cucumis melo</i> var. <i>conomon</i> dose-dependently triggers differentiation and apoptosis of RCM-1 human colorectal cancer cells. 2023 , 48, 25-35	0

- 15 Novel Insights into the Role of Kras in Myeloid Differentiation: Engaging with Wnt/ β Catenin Signaling. **2023**, 12, 322
- 14 The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. 12,
- 13 Synergistic Anti-Cancer Activity of the Combination of 1,25-Dihydroxyvitamin D3 and Retinoic Acid in U937 Cell Line. **2022**, 11, 440-449
- 12 Repurposing Drugs in Small Animal Oncology. **2023**, 13, 139
- 11 Pharmaceutical/Clinical Strategies in the Treatment of Acute Promyelocytic Leukemia: All-Trans Retinoic Acid Encapsulation by Spray-Drying Technology as an Innovative Approach—Comprehensive Overview. **2023**, 16, 180
- 10 La leucémie aiguë promyélocytaire: un paradigme de la guérison par les traitements ciblés. **2023**, 207, 423-430
- 9 Comparison of maintenance regimens in Acute Promyelocytic Leukemia patients. **2023**, 128, 107055
- 8 Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale. 13,
- 7 Overexpression of CASP1 triggers acute promyelocytic leukemia cell pyroptosis and differentiation. **2023**, 945, 175614
- 6 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178
- 5 Prospective Identification of Prognostic Hot-Spot Mutant Gene Signatures for Leukemia: A Computational Study Based on Integrative Analysis of TCGA and cBioPortal Data.
- 4 Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?. **2023**, 43, 227-239
- 3 Prediction model for drug response of acute myeloid leukemia patients. **2023**, 7,
- 2 CADD for Cancer Therapy: Current and Future Perspective. **2023**, 325-363
- 1 Epigenetic regulation by ASXL1 in myeloid malignancies.